Neurogastrx, Inc.  NG101 -201 
 
CONFIDENTIAL  1 Title Page 
Protocol Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 
Study of the Safety and Efficacy of NG101 Administered Orally to Patients with 
Gastroparesis 
Protocol Number:  NG101 -201 
Amendment Number: Not applicable 
Compound: NG101  (metopi[INVESTIGATOR_112118])  
Study Phase:  2  
Acronym:  Not applicable 
Sponsor Name:  [CONTACT_112250], Inc.  
Legal Registered Address:  [ADDRESS_124986], Woburn, MA [ZIP_CODE], [LOCATION_003] 
Regulatory Agency Identifier Number(s) :  
Approval Date: 08 November 2019 
Protocol Version:  Original  
  

Neurogastrx, Inc.  NG101 -[ADDRESS_124987] Research 
Organization (CRO) Medical Monitor  
 
 
 
Clinical Laboratory   
 
 
 
 
CRO Contact   
 
 
 
[CONTACT_112210], Facsimile, and Email    
  
 
 
  
  
 
 
  

Neurogastrx, Inc.  NG101 -201 
 
CONFIDENTIAL  4 Table of Contents  
1. Protocol Summary ..........................................................................................................8  
1.1. Synopsis ............................................................................................................................8  
1.2. Schema  ............................................................................................................................12  
1.3. Schedule of Activities (SoA) ..........................................................................................13  
2. Introduction ...................................................................................................................20  
2.1. Nonclinical ......................................................................................................................20  
2.2. Clinical Experience  .........................................................................................................20  
2.2.1.  Phase 1 Studies  ...............................................................................................................20  
2.2.2.  Previous Human Experience ...........................................................................................24  
2.3. Study Rationale ...............................................................................................................25  
2.4. Background .....................................................................................................................25  
2.5. Benefit / Risk Assessment  ..............................................................................................26  
2.5.1.  Risk Assessment  .............................................................................................................27  
2.5.2.  Benefit Assessment  .........................................................................................................30  
2.5.3.  Overall Benefit: Risk Conclusions ..................................................................................30  
3. Objectives an d Endpoints  ............................................................................................31  
4. Study Design ..................................................................................................................34  
4.1. Overall Design  ................................................................................................................34  
4.2. Scientific Rationale for Study De sign ............................................................................35  
4.2.1.  Participant Input into Design  ..........................................................................................36  
4.3. Justification for Dose  ......................................................................................................36  
4.4. End of Study Definition ..................................................................................................37  
5. Study Population  ...........................................................................................................38  
5.1. Inclusion Criteria  ............................................................................................................38  
5.2. Exclusion Criteria  ...........................................................................................................40  
5.3. Lifestyle Considerations  .................................................................................................43  
5.3.1.  Meals and Dietary Restrictions  .......................................................................................43  
5.3.2.  Caffeine, Alcohol, and Tobacco .....................................................................................43  
5.3.3.  Activity  ...........................................................................................................................43  
5.4. Screen Failures  ................................................................................................................43  
5.5. Pretreatment Period Failures  ...........................................................................................44  
6. Study Drug  ....................................................................................................................45  
6.1. Study Drug(s) Administered ...........................................................................................45  
6.2. Preparation / Handling / Storage / Accountability  ..........................................................46  
6.3. Measures to Minimize Bias: Randomization and Blinding  ............................................47  
6.4. Study Compliance ...........................................................................................................47  
6.5. Concomitant Therapy .....................................................................................................48  
6.5.1.  Rescue Medicine  .............................................................................................................48  
6.6. Dose Modification  ..........................................................................................................49  
6.7. Intervention after the End of the Study  ...........................................................................49  
7. Discontinuation of Study Drug and Participant 
Discontinuation  / Withdrawal......................................................................................50  
Neurogastrx, Inc.  NG101 -201 
 
CONFIDENTIAL  5 7.1. Discontinuation of Study Drug .......................................................................................50  
7.1.1.  Temporary Interruption  ...................................................................................................51  
7.1.2.  Reinitiation  ......................................................................................................................51  
7.2. Participant Discontinuation / Withdrawal from the Study ..............................................[ADDRESS_124988]  ....................................................................................................55  
8.3. Efficacy Assessments  .....................................................................................................55  
8.3.1.  Diabetic and Idiopathic Gastroparesis Symptoms Daily Diary 
(DIGS -DD) .....................................................................................................................55  
8.3.2.  Gastroparesis Cardinal Symptom Index Daily Diary (GCSI- DD) .................................56  
8.3.3.  Patient Assessment of Upper Gastrointestinal Disorders -
Symptoms Questionnaire  ................................................................................................56  
8.3.4.  Patient Assessment of Upper Gastrointestinal Disorders -Quality 
of Life Questionnaire  ......................................................................................................56  
8.3.5.  Nausea Profile  .................................................................................................................57  
8.3.6.  Patient Global Impression of Severity Questionnaire  .....................................................57  
8.3.7.  Patient Global Impression of Change Questionnaire  ......................................................57  
8.3.8.  Treatment Satisfaction Assessment  ................................................................................57  
8.3.9.  Nausea Improvement  ......................................................................................................57  
8.4. Safety Assessments  .........................................................................................................58  
8.4.1.  Physical Examinations  ....................................................................................................58  
8.4.2.  Vital Signs  .......................................................................................................................58  
8.4.3.  Electrocardiograms  .........................................................................................................59  
8.4.4.  Clinical Safety Laboratory Assessments  ........................................................................59  
8.5. Adverse Events and Serious Adverse Events .................................................................60  
8.5.1.  Time Period and Frequency for Collecting AE and SAE Information  .....................................................................................................................60
 
8.5.2.  Method of Detecting AEs and SAEs ..............................................................................60  
8.5.3.  Follow-up of AEs and SAEs ...........................................................................................60  
8.5.4.  Regulatory Reporting Requirements for SAEs ...............................................................60  
8.5.5.  Pregnancy ........................................................................................................................61  
8.5.6.  Disease-Related Events and/or Dis ease-Related Outcomes Not 
Qualifying as AEs or SAEs  .............................................................................................[ADDRESS_124989]  .................................................................................62  
8.6. Treatment of Overdose  ...................................................................................................63  
8.7. Pharmacokinetics  ............................................................................................................64  
8.7.1.  Pharmacokinetic Assessment Methods and Timing .......................................................64  
8.8. Pharmacodynamics .........................................................................................................66  
8.9. Genetics  ..........................................................................................................................67  
8.10.  Biomarkers  ......................................................................................................................67  
8.11.  Immunogenicity Assessments .........................................................................................67  
8.12.  Healthcare Resource Utilization  .....................................................................................68  
9. Statistical Considerations  .............................................................................................69  
Neurogastrx, Inc.  NG101 -201 
 
CONFIDENTIAL  6 9.1. Sample Size Determination  ............................................................................................69  
9.2. Populations for Analyses ................................................................................................69  
9.3. Statistical Analyses  .........................................................................................................69  
9.3.1.  General considerations  ....................................................................................................69  
9.3.2.  Efficacy Endpoints ..........................................................................................................70  
9.3.3.  Key Secondary Efficacy Endpoints ................................................................................71  
9.3.4.  Additional Secondary Efficacy Endpoints ......................................................................71  
9.3.5.  Exploratory Endpoint(s)  ..................................................................................................72  
9.3.6.  Safety Endpoints .............................................................................................................73  
9.4. Interim Analyses  .............................................................................................................73  
9.5. Data Monitoring Committee (DMC) and Data Safety Monitoring 
Board (DSMB)  ................................................................................................................73  
10. Supporting Documentation and Operational Considerations  ..................................74  
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ................................................................................................................74
 
10.1.1.  Regulatory and Ethical Considerations  ...........................................................................74  
10.1.2.  Financial Disclosure  ........................................................................................................74  
10.1.3.  Informed Consent Process ..............................................................................................75  
10.1.4.  Data Protection ................................................................................................................75  
10.1.5.  Committees Structure ......................................................................................................75  
10.1.6.  Dissemination of Clinical Study Data  .............................................................................75  
10.1.7.  Data Quality Assurance  ..................................................................................................76  
10.1.8.  Source Documents ..........................................................................................................76  
10.1.9.  Study and Site Start and Closure ....................................................................................77  
10.1.10.  Publication Policy  ...........................................................................................................77  
10.2.  Appendix 2: Prohibited and Permitted Medications .......................................................78  
10.3.  Appendix 3: Clinical Laboratory Tests ...........................................................................81  
10.4.  Appendix 4: Patient Reported Outcomes for Efficacy Assessments  ....................................................................................................................83
 
10.5.  Appendix 5: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow -up, and Reporting .........................................................85
 
10.5.1.  Definition of AE  .............................................................................................................85  
10.5.2.  Definition of SAE  ...........................................................................................................86  
10.5.3.  Recording and Follow-Up of AE and/or SAE ................................................................87  
10.5.4.  Reporting of SAEs ..........................................................................................................89  
10.6.  Appendix 6: Contraceptive Guidance and Collection of Pregnancy Information ...................................................................................................90
 
10.7.  Appendix 7: Estimated Glomerular Filtration Rate  ........................................................93  
10.8.  Appendix 8: Genetics......................................................................................................94  
10.9.  Appendix 9: Abbreviations .............................................................................................[ADDRESS_124990] of Tables  
Table 1:  Study Drugs ....................................................................................................... 45  
Table 2:  Total Volume of Blood Required for Each Assay  ............................................ 54  
Table 3:  Adverse Events of Special Interest: Rationale for Inclusion and Criteria for 
Diagnosis .......................................................................................................... 62  
Table 4: Pharmacokinetic Sampling Times  ..................................................................... 65  
Table 5:  Serum Prolactin Sampling Times  ...................................................................... 67  
Table 6:  Protocol- Required Safety Laboratory Assessments  .......................................... 81  
 
Neurogastrx, Inc.  NG101 -201 
 
CONFIDENTIAL  10 • Association of exposure and clinical 
response • Association of PK parameters and changes in gastroparesis symptom PRO scores.  
• Association of PK parameters and safety assessments  
• Additional analyses of clinical response in gastroparesis symptoms  • Achievement of threshold levels of improvement or worsening in each of the 
components of the DIGS -DD (nausea, 
vomiting, early satiety, post -prandial 
fullness, and abdominal pain)  
• Composite symptom severity scores  
• Healthcare resource utilization  • Number of visits to healthcare provider s 
• Association of serum glucose with clinical 
response • Association of serum glucose levels and 
HgbA1c with gastroparesis symptom PRO scores  
Abbreviations: DIGS -DD = Diabetic and Idiopathic Gastroparesis Symptoms Daily Diary; 
ECG  = electrocardiogram; GCSI -DD = Gastroparesis Cardinal Symptom Index Daily Diary; 
PAGI- SYM  = Patient Assessment of Upper Gastrointestinal Disorders -Symptoms Questionnaire; 
PAGI- QOL  = Patient Assessment of Upper Gastrointestinal Disorders -Quality of Life; PGI -C = Patient Global 
Impression of Change; PGI -S = Patient Global Impression of Severity; PD = pharmacodynamic; 
PK = pharmacokinetic; PRO = patient -reported outcomes; TEAEs = treatment -emergent adverse e vents; 
TEAESIs = treatment -emergent adverse events of special interest; TESAEs = treatment -emergent serious adverse 
events.  
Overall Design 
This is a randomized, double- blind, parallel -group (4 arms), placebo- controlled, multicenter 
study to evaluate the safety and efficacy of 3 dose levels of NG101 compared with placebo in 
participants with diabetic or idiopathic gastroparesis.  
Following a Screening Period of up to 4- weeks, eligible participants will enter a 2 -week 
Pretreatment Period , during which time they will complete specified gastroparesis symptom 
assessments to establish baseline data and to determine compliance with completion of these 
assessments. Following completion of the Pretreatment Period, a participant’s randomization 
eligibility will be determined (based on all inclusion/exclusion criteria, including the participant’s compliance with eDiary completion).  
Participants who do not initially meet study screening criteria (ie, are screen failures) may be rescreened (no more than 1 additional screening) after consultation with and approval by [CONTACT_456] . A participant’s eligibility for the study must be confirmed by [CONTACT_456] ’s Medical 
Monitor, or designee, prior to randomization. 
Participants eligible for the clinical study will be randomized i n a 1:1:1:1 ratio to receive either 
NG101 treatment arms of 5 mg, 10 mg, or 20 mg, or matching placebo during a 12- week 
Treatment Period. Randomization will be stratified on the following factors: gastroparesis 
etiology (diabetes vs idiopathic), sex (male vs female), and cannabinoid use (yes vs no). Determination of diabetes etiology will be done according to the medical history data at 
Screening. 
Neurogastrx, Inc.  NG101 -201 
 
CONFIDENTIAL  11 Two weeks following the Week 12 Visit , participants will return to the clinic for an End of Study 
(EoS) Visit /  Follow- up Visit.  
If a participant permanently discontinues study medication (for any reason) prior to the Week [ADDRESS_124991] attend the Early Discontinuation Visit as soon as possible, and then 
the Safety Follow -up Visit 2 weeks later.  
Study Assessments:  
Study assessments will be performed at the times specified in the Schedule of Activities (SoA  – 
see Section 1.3).  
The primary efficacy objective is to determine the efficacy of NG101 to reduce nausea severity 
in participants with gastroparesis. The primary endpoint is the change from baseline at Weeks 7 
through 12 for the nausea severity score in the Diabetic and Idiopathic Gastroparesis Symptoms 
Daily Diary (DIGS -DD). Key secondary efficacy endpoints will also be assessed by [CONTACT_112211] -DD and include changes from baseline at Weeks [ADDRESS_124992] -prandial fullness severity score, 
abdominal pain severity score , and total severity score (nausea, early satiety, post -prandial 
fullness, abdominal pain).  An eDiary will be used to collect information for the primary and key 
secondary endpoints.  
In addition, blood samples will be obtained from all participants to measure plasma levels of 
metopi[INVESTIGATOR_112119] -dose administration (Day 1) and at 
steady -state after multiple -dose administration (Week 2). Blood samples for PK will be collected 
at the Day 1 and Week 2 visits for all participants (up to [ADDRESS_124993] dose on each occasion) . In a subset of participants  (8 to 10 participants per treatment arm; 32 to 40 participants 
total), intensive sampling will be performed (up to [ADDRESS_124994] dose at the Day 1 and Week 2 visits, as well as 1 and 2 hours after the second dose at the Day 1 visit). 
Disclosure Statement :  
This is a parallel group treatment study with 4 arms that is participant, i nvestigat or, and sponsor  
blinded.  
Number of Participant s: 
A total of approximately 280 participants will be randomized to achieve an estimated 
224 participants completing the 12 -week T reatment Period (and approximately 56 participants 
per treatment arm). At least [ADDRESS_124995] idiopathic gastroparesis.  Up to approximately 
140 participants can  be cannabinoid users, and of these, up to approximately 56 can be marijuana 
users.  
Intervention Groups  and Duration: 
The total duration of the study for each participant will be approximately 20 weeks. 
On Day 1 of the Treatment Period, eligible participants will be randomized in a 1:1:1:1 ratio to 
receive either NG101 5 mg, 10 mg, or 20 mg, or matching placebo. Study drug will be 
administered orally 4 times per day (QID) for [ADDRESS_124996]: 
A Data Monitoring Commi ttee (DMC) comprised of representatives from the sponsor and CRO 
will review blinded data on an ongoing basis.  
An unblinded independent safety review conducted by a Data Safety Monitoring Board  (DSMB ) 
will be triggered  if any of the following conditions are met: 3 or more participants in the study 
exhibit extrapyramidal symptoms ( EPS); [ADDRESS_124997] neuroleptic malignant 
syndrome (NMS); 3 or more participants are discontinued due to orthostatic hypotension- related 
adverse events (A Es); other events considered of high clinical significance by [CONTACT_112212]. The DSMB will then make any recommendations to the sponsor regarding conduct of 
the study. 
1.2. Schema  
 
 

Neurogastrx, Inc.  NG101 -201 
 
CONFIDENTIAL  20 2. Introduction  
NG101 is a potent and selective, peripherally- restricted (ie, very limited ability to penetrate the 
brain), human Ether-à-go-go- related gene  (hERG) negative (ie, no hERG inhibition at expected 
human plasma exposures), dopamine D 2/D3 receptor antagonist bei ng evaluated for the treatment 
of gastroparesis. It is also an antagonist with lower affinity for dopamine D 1, adrenergic alpha-1, 
histamine H 1, and serotonin 5- HT 2A/5-HT 2B receptors.  
2.1. Nonclinical  
A complete battery of studies has been conducted to support the safety of the proposed clinical 
trial in accordance with International Conference of Harmonisation ( ICH) M3(R2). Based upon 
the metabolism and pharmacologic properties of NG101, the rat and dog were considered 
appropriate models for pi[INVESTIGATOR_112120] l safety studies. NG101 was administered by [CONTACT_112213][INVESTIGATOR_112121], as it is the intended route of administration for clinical trials and marketing.  
Briefly, the nonclinical program confirmed that metopi[INVESTIGATOR_112122] (tested as NG101) is a  
P-glycoprotein substrate with limited penetration of the blood-brain barrier. NG101 is not 
metabolized via the cytochrome P450 pathway, thereby [CONTACT_112214]-drug interactions. Unlike domperidone, NG101 does not produce hERG channel inhibition at expected 
human plasma exposures. There is a > 100-fold window between expected free plasma 
concentrations in the proposed Phase 2 study and the hERG half maximal inhibitory concentration (IC50) determined in vitro. Nonclinical studies also demonstr ated that 
metopi[INVESTIGATOR_112123] > 100 -fold lower affinity to D
2 and D 3 receptors as compared to the 
parent drug metopi[INVESTIGATOR_112122].  
Effects seen in the toxicology studies were anticipated given the mechanism of action of 
metopi[INVESTIGATOR_112122], and are able to be monitore d in the clinic.  These include effects related to 
increased prolactin levels (see Section 2.5.1).  
See the NG101 Investigator’s Brochure (IB) for further details.  
2.2. Clinical Experience  
2.2.1. Phase [ADDRESS_124998] been conducted by [CONTACT_112215][INVESTIGATOR_112124]: Study NG100-101 and Study NG101-102. A summary of both studies is provided below and further details can be found in the NG101 IB . 
Neurogastrx, Inc.  NG101 -201 
 
CONFIDENTIAL  21 [IP_ADDRESS]. Study NG100 -101 (SAD / MAD Study)  
Study Design 
Study NG100-101 was a phase 1 double-blind, placebo- controlled, single-ascending and 
multiple -ascending dose (SAD and MAD) study of the safety, tolerability, and PK of 
metopi[INVESTIGATOR_112125] s ages [ADDRESS_124999] administered in this study was the 
French approved and marketed brand of metopi[INVESTIGATOR_112122], Vogalene. 
In the SAD portion of the study a total of 4 cohorts were enrolled and single ascending doses of 
15, 30, 45, and 60 mg were tested. A total of 32 participants (16 females, 16 males) were 
randomized, and all participants completed the SAD portion of the study. 
In the MAD portion of the study, sequential multiple -ascending doses were evaluated in 
3 cohorts of 8 participant s. Dosing regimens of 15, 30, and 45 mg, were administered every 
6 hours (Q6H) for 5 days, followed by a single dose on Day 6. A total of 24  participant s 
(12 females, 12  males) were randomized , and 23 participants completed part 2 (12 females, 
11 males).  
Results  
Pharmacokinetics 
Following dosing with metopi[INVESTIGATOR_112122] , maximum plasma concentration ( Cmax) occurred at a 
median time of 0.8 to 1.1 hours after dosing with median lag time from 0.1 to 0.25 hours after 
dosing. A high inter-individual variability was observed f or C max of metopi[INVESTIGATOR_112126] (%CV) ranging from 46 to 75%. The area under the plasma 
concentration -time curve (AUC) from time 0 to infinity (AUC 0-inf) and derived pharmacokinetic 
(PK) parameters of metopi[INVESTIGATOR_112122] ( terminal half -life [t1/2], total clearance [Cl/F ] and V z/F) could 
be estimated at doses of 30  mg and above. The mean t 1/2 ranged from 2 to 2.3 hours, Vz/F ranged 
from 430 to 860 L and Cl/F ranged from 170.5 to 335 L/h. Mean PK parameters of 
metopi[INVESTIGATOR_112127] C max and AUC with dose from [ADDRESS_125000] variability. Mean PK  parameters 
increased with higher doses in a manner that was close to dose-proportional over a dose range of 15 to 60 mg for single doses and 15 to 45 mg for multiple doses.   
Following administration of multiple doses every 6 hours (Q6H) , steady -state conditions 
appeared to be reached by [CONTACT_112216] 1. After continued Q6H dosing through Day 6, 
metopi[INVESTIGATOR_112128] 30 to  40% based on AUC.   
Metopi[INVESTIGATOR_112129], with metopi[INVESTIGATOR_112130] C
max 
occurring at median times ranging from 2 to 3 hours after dosing across cohorts. The mean metopi[INVESTIGATOR_112131] t
1/[ADDRESS_125001] measurable concentration ( AUC 0-last) and 
AUC 0-inf. Accumulation of metopi[INVESTIGATOR_112132] (Q6H ) with a 
mean accumulation ratio  of 1.6 to 1.7 based on C max and 1.7 to 1.9 based on AUC 0-6. 
Neurogastrx, Inc.  NG101 -201 
 
CONFIDENTIAL  22 Safety 
No serious adverse events ( SAEs ) were observed during the study, and no participants withdrew 
due to adverse events (AEs). All adverse events (AEs) were reported to be mild or moderate in 
severity. No symptoms suggestive of neuroleptic malignant syndrome ( NMS ) or extrapyramidal 
symptoms ( EPS) were observed and there were no clinically relevant changes in 
electrocardiogram (ECG ) time intervals. No notable trends were observed in changes in 
laboratory tests.  
An increased risk of orthostatic hypotension (OH) was observed with metopi[INVESTIGATOR_112122], likely due to inhibition of peripheral adrenergic alpha -1 receptors. Orthostatic changes in vital signs 
considered to be clinically significant were defined as a decrease in systolic or diastolic blood 
pressure ( BP) of at least [ADDRESS_125002] 
30 beats/minute and/or heart rate above 120 beats/minute  (Freeman et al. 2011; NIH- NINDS 
Postural Tachycardia Syndrome Information Page  2019).  
In the 15 mg and 30 mg groups of the SAD portion of the study, 1 to 2 participants (out of 6 in 
each dose group) were reported to have “dizziness in standing position”. No vital sign measurements were obtained at the time of these events; however, the preferred term of OH was 
recorded. A protocol amendment was implemented after cohort 2 (30 mg) of the SAD portion of 
the study to require vital sign measurements lying, sitting, and standing at prescribed timepoints after dosing. In the 45 mg and 60 mg groups of the SAD, 4 participants ( out of 6 in each dose 
group) experienced OH.   
Two participants in the MAD 15 mg Q6H group experienced OH (on Day [ADDRESS_125003] dose ) and 1 participant  in the MAD 30 mg Q6H group experienced OH (on Day [ADDRESS_125004] dose ). No ot her epi[INVESTIGATOR_112133] s, and no other participants in these dose groups experienced OH. On the other hand, 
most participants in the MAD [ADDRESS_125005] that with repeat dosing, participants adapt to the alpha-adrenergic inhibition, which is 
consistent with the literature on alpha -1 receptor antagonists approved for use in hypertension 
and benign prostatic hyperplasia  (Achari et al. 1998). 
[IP_ADDRESS]. Study NG10 1-102 (Comparative PK Study) 
Study Design 
Study NG101-102 was a phase 1 two-cohort, partial crossover, open- label, randomized, single -
dose study to assess the relative bioavailability between NG101 (metopi [INVESTIGATOR_112118]) and 
the reference metopi[INVESTIGATOR_112134] (Vogalene) in healthy participant s at a single study 
center in [LOCATION_009]. The NG101 dose (15 mg) for Cohort 2 of the study was determined from the 
PK results from Cohort 1 of the study. The reference  metopi[INVESTIGATOR_112135] a 15  mg capsule or via a diluted intravenous ( IV) infusion of a 10 mg/mL solution 
administered as 7.5  mg over 60 minutes. 
Neurogastrx, Inc.  NG101 -201 
 
CONFIDENTIAL  23 Cohort 1 was a 3-period, partial crossover in the fasted state with 3 administrations of NG101 
7.5 mg PO, Vogalene 15 mg PO, or Vogalene 7.5 mg IV. There was a wash -out period of 
48 hours between each administration. A total of 8 participants were enrolled and received each 
of the 3 treatments.  
Cohort 2 was a 3-period, cross- over design with 3 administration s of 15 mg of each of the 
following : oral formulation of NG101 fasting, oral formulation of NG101 after a high- fat 
breakfast, oral formulation of the reference metopi[INVESTIGATOR_112136].  There was a wash -out period 
of [ADDRESS_125006] squares mean ratio, preliminary estimates of the relative 
bioavailability of NG101 compared to Vogalene, each under fasting conditions, were 109% for 
AUC
last and 86.4% for C max, but the 90% confidence intervals (CIs) were too wide to conclude 
equivalence. A high degree of inter-subject v ariability was observed for these PK parameters and 
several participant s had plasma concentrations below the limit of quantification (5 ng/mL) within 
the first 6 hours after dosing. An elimination t 1/2 for metopi[INVESTIGATOR_112137] ; therefore, AUC 0-inf could not be calculated. Given that the time of last 
measurable plasma metopi[INVESTIGATOR_112138] s for the different study 
treatments, an additional exploratory PK in which AUC last was uniformly truncat ed at the time of 
last measurable concentration showed a relative bioavailability of 98%. For metopi[INVESTIGATOR_112130], 
the 2 formulations met bioequivalence criteria with geometric mean ratios of 92.2% and 93.1% 
for AUC last and C max respectively . 
Overall, NG101 provided generally similar exposure to metopi[INVESTIGATOR_112139], although the current limit of quantification for metopi[INVESTIGATOR_112122] (5 ng/mL) 
limited some of the PK objectives.  
For metopi[INVESTIGATOR_112122], administration of NG101 with a high- fat breakfast resulted in an approximate 
15% reduction in C max and an approximate 5% reduction in AUC last with 90% CIs outside of the 
bioequivalence range. An additional exploratory PK analysis was performed in which AUC last 
was uniformly truncated at the time of last measurable concentration for each participant, which 
showed a 12% reduction in AUC last with a high -fat breakfast. For metopi[INVESTIGATOR_112130], NG101 
given with a high fat breakfast resulted in a 30% reduction in C max and a 27% reduction in 
AUC last. Overall, these PK differences are unlikely to be of clinical significance.  
Pharmacokinetics 
For the NG101 7.5 mg dose, few timepoints after C max were quantifiable above the limit of 
quantification (5 ng/mL) with the time of the last measurable concent ration (T last) ranging from 
1.25 to 2 hours. As such, the terminal elimination rate constant (Lambda z) and the derived 
parameters (t 1/2, AUC inf, Cl/F and Vd/F) could not be reliably determined. For the [ADDRESS_125007] ranged from 2 to 6 hours a nd terminal t 1/2 for metopi[INVESTIGATOR_112140] 2/[ADDRESS_125008], NG101 appeared to result 
Neurogastrx, Inc.  NG101 -201 
 
CONFIDENTIAL  24 in approximately 50% lower and absolute relative bioavailability; however, this determination 
was influenced by [CONTACT_112217][INVESTIGATOR_112141]. When the AUC was 
limited uniformly to [ADDRESS_125009]-dose, metopi[INVESTIGATOR_112142]- adjusted AUC in participants 
administered NG101 was approximately 91% compared to those administered Vogalene. For the 
metopi[INVESTIGATOR_112143], the relative bioavailability based on dose -adjusted AUC last was 
approximately 86%.  The absolute bioavailability of Vogalene was approximately 19% (also 
based on AUC last), which is consistent with published studies ( Herrstedt et al. 1990). The results 
from Cohort [ADDRESS_125010] values were 20.6 ng/mL and 39.9 ng.h/mL, respectively. A lag 
time of 0.25 hours (median) was observed after dosing. The terminal elimination rate constant 
(Lambda z) and the derived parameters (t 1/2, AUC inf, Cl/F and Vd/F) could not be reliably 
determined. A high inter- individual variability was observed with %CV between 60.4 and 
82.6%. Metopi[INVESTIGATOR_112122] C max and AUC 0-2h appeared to be approximately dose proportional 
between the 7.5 mg dose of NG101 in Cohort 1 and the 15 mg dose in Cohort 2. 
Safety No serious adverse events (SAEs) were observed during the study, and no participants withdrew 
due to adverse events (AEs). All adverse events (AEs) were reported to be mild or moderate in 
severity.  In each of the three 15- participant treatment groups, 2 to 4 participants reported AEs 
that were related to postural change (consistent with results observed in the SAD / MAD study) . 
However, no consistent pattern was observed within individual participant s across the treatments 
(ie, some participants had the AEs with 1 treatment but not another). A small increased risk of orthostatic related AEs was observed upon fasting (ie, 3 fasting versus 1 fed). All OH events 
occurred at 1  hour after dosing, with the exception of 1 OH event that occurred at hour 8. There 
were  no other trends indicative of clinically important treatment- related laboratory abnormalities.   
2.2.2. Previous Human Experience  
Metopi[INVESTIGATOR_112122] (Vogalene
®) has been used extensively as an antiemetic for over 40 years in 
[LOCATION_009]. In a dose -ranging open- label safety and tolerability study involving 38 patients 
undergoing chemotherapy, metopi[INVESTIGATOR_112144] 4 hours at increasing 
doses ( Herrstedt et al. 1997a ). A total of 36 patients completing 46 cycles of chemotherapy 
received 20, 30, 40, 50 and 60 mg oral metopi[INVESTIGATOR_112145] 4 hours over a 44-hour period. The 
metopi[INVESTIGATOR_112146]- limiting toxicity  was moderate to severe dizziness caused by [CONTACT_112218], as seen in 
0, 0, 17%, 42% and 50% of the patients at the respective dose levels. No  information was 
provided on the timing of the occurrence of dizziness during the 44-hour period. Few o ther side 
effects were reported, and most were mild . A single possible extrapyramidal AE was observed in 
a patient in the 60 mg x 11 dose group. M etopi[INVESTIGATOR_112147] a dosage of 
30 mg, 6 times (180 mg) daily.  
Further, in a randomized, double-blind comparison of ondansetron vs ondansetron plus 
metopi[INVESTIGATOR_112148]- based chemotherapy in patients with 
cancer, metopi[INVESTIGATOR_112149] 35  mg/m2 IV followed by 30 mg, 4 times a 
Neurogastrx, Inc.  NG101 -201 
 
CONFIDENTIAL  25 day (120 mg daily), for 4 days. A total of 94 patients completed the crossover study. Results 
suggested  that metopi[INVESTIGATOR_112150] . Reported adverse reactions were mild and without 
significant differences between the 2 treatments. However, an asymptomatic decrease in  standing 
BP was observed when patients received the combination antiemetic therapy 
(Herrstedt et al. 1997a ).  
In a randomized, double- blind trial assessing the efficacy and safety of sublingual metopi[INVESTIGATOR_112151]-induced delayed emesis, patients received either 45 mg/day of metopi[INVESTIGATOR_112122] (15 mg every 8 hours) or 16 mg/day of ondansetron (8 mg every 
12 hours). Metopi[INVESTIGATOR_112152]. Furthermore , the incidence 
of gastrointestinal (GI ) disorder s was significantly lower in the metopi[INVESTIGATOR_112153], particularly 
abdominal pain and constipation ( Herrstedt et al.  1997b; Bethune- Volters et al.  2006 ).  
Since metopi[INVESTIGATOR_112154] (10 January 1977), a number of 
other open-label or randomized, placebo-controlled efficacy studies involving oral or IV 
administration of metopi[INVESTIGATOR_112155]. These studies conclude that metopi[INVESTIGATOR_112156] ( CNS ) or 
cardiovascular ( CV) AE s (Paradis and Brault 1967 ; Guerin  et al. 1969; Arbus and Parente 1971; 
Berry et al.  1971; Arnaud and Sportouch 1972; Bertrand and Thillier 1975; Barale et al.  1977; 
Israel  1978; Rodary et al. 1979; Ballester  et al 1980; Gosselin  et al 1981 ; Badji et al  1988; 
Herrstedt et al. 1990; Herrstedt et al. 1997b; Lebeau  et al. 1997; Sigsgaard et al. 2001 ; 
Croom and Keating 2006).  
Generally, studies in chemotherapy-induced nausea and vomiting suggest that doses of 
metopi[INVESTIGATOR_112157]. Doses ranging from 45  to 120 mg per 
day were evaluated in these studies ( Israel and Rodary 1978; Herrstedt et a l. 1997b; 
Lebeau  et al. 1997; Sigsgaard et al. 2001; Bethune- Volters et al.  2006 ). 
2.3. Study Rationale  
The purpose of this study is to evaluate the safety and efficacy of NG101  when administered 
orally across a range of 3 doses to pa rticipants aged 18 years or older with diabetic or idiopathic 
gastroparesis.  Results of this study will guide optimal dose selection for phase 3. 
2.4. Background  
Gastroparesis is a chronic disorder of the stomach  characterized by [CONTACT_112219] ( Camilleri et al. 201 3; Stein  et al. 2015 ). The core 
set of  symptoms of gastroparesis include nausea, vomiting, early satiety, post -prandial fullness, 
and abdominal pain ( Food and Drug Administration [ FDA] 2019;  Camilleri et al. 2013 ). Th e 
most common etiologies of g astroparesis are of  idiopathic and  diabetic origin ( Parkman  2018; 
Camilleri et al. 2013 ). While the o verall incidence of gastroparesis is not well understood, the 
10-year incidence in Olmsted County Minnesota, U nited States (US), was 5.2% in patients with 
type 1 diabetes, 1% in patients with type 2 diabetes, and 0.2% among non- diabetic controls 
(Choung et  al. 2012). Evidence suggests gastroparesis is associated with increased healthcare 
costs, including an increased  frequency of hospi[INVESTIGATOR_602] ( Wadhwa et  al. 2017; 
Neurogastrx, Inc.  NG101 -201 
 
CONFIDENTIAL  26 Camilleri et  al. 2013). Overall, gastroparesis adversely affects the lives of patients, and there is 
urgent need to develop treatments with a favorable risk -benefit profile.  
Neurogastrx, Inc. is developi[INVESTIGATOR_112158]101, a mesylate salt of metopi[INVESTIGATOR_112122], a potent and selective, 
peripherally -restricted (ie, very limited ability to penetrate the brain), hERG negative (ie, no 
hERG inhibition at expected human plasma exposures), dopamine D 2/D3 receptor antagonist for 
the treatment of gastroparesis. Metopi[INVESTIGATOR_112122] (oral capsules, orally disintegrating tablet, 
suppositories, liquid drops or syrup) has been approved in [LOCATION_009] for over 40 years under the 
current trade name [CONTACT_112251]® (15 mg oral capsule; 7.5 mg orally disintegrating tablet) for the 
short- term symptomatic treatment of nausea and vomiting.   An IV formulation (10 mg) is 
approved and is almost exclusively used for the treatment of chemotherapy-induced nausea and vomiting in adults and children. The vast majority of prescriptions for adults and 
infants  / children are for seasonal gastroenteritis or acute nausea and vomiting of various 
etiologies. Metopi[INVESTIGATOR_112159] -the-counter medication (Vogalib
®, 7.5 mg 
orally disintegrating tablets).  
Dopamine antagonism has been well validated as an effective treatment for gastroparesis. Metoclopramide and domperidone , existing D
[ADDRESS_125011] gastroprokinetic properties as 
well as anti -nausea/anti -emetic effects . However, these agents are associated with limiting CNS 
and CV side effects, respectively. Although metopi[INVESTIGATOR_112160] (most of which are associated with CNS and/or CV side effects),  its use is rarely  
associated with  CNS side effects, and has not been associated with significant cardiac risk  when 
used at the current marketed doses in [LOCATION_009]. As such, NG101  is a promising candidate for the 
treatment of gastroparesis .   
A detai led description of the chemistry, pharmacology, efficacy, and safety of metopi[INVESTIGATOR_112161]101 IB.  
2.5. Benefit  / Risk Assessment  
A summary of the benefit-risk assessment for conducting Study NG101 -201 is provided in the 
following sections ( Secti on 2.5.1, Section 2.5.2, and Section 2.5.3). 
More detailed information about the known and expected benefits and risks and reasonably 
expected  AEs of NG101  may be found in the IB. 
Neurogastrx, Inc.    NG101 -201 
 
CONFIDENTIAL  28 Potential Risk of 
Clinical Significance  Summary of Data /  
Rationale for Risk   Mitigation Strategy 
continued AEs. Participants wi th recurrent postural AEs on subsequent days will 
return to the study site for further evaluation.  
Individual stoppi[INVESTIGATOR_3418]: 
Participants with OH (defined by a decrease in sy stolic BP of at least 20  mm Hg) 
and associated severe postural symptoms will be stopped and withdrawn from 
the study.   
These severe symptoms include presyncope, syncope, and other severe AEs that 
are considered of substantial clinical relevance by [CONTACT_74169]. Presyncope is 
defined as “feeling like one was going to pass out but without actual loss of 
consciousness” (Whitledge et al. 2019). Syncope is “the sudden loss of 
consciousness, associated with inability to maintain postural tone, with 
immediate and spontaneous recovery without requiring electrical or chemical 
cardioversion” (da  Silva 2014 ). 
Participants meeting this discontinuation criterion while under observation 
during clinical visits must be monitored in the clinic until postural symptoms are 
no longer severe, and will be withdrawn from the study. Participants who 
develop severe postural symptoms at home will hold any further dosing and return to the study site as soon as possible for further evaluation.  
Other mitigation:  
Participants in the 20 mg treatment arm will be initiated with a dose titration, beginning with daily dosing with 5 mg 4 times daily ( QID). 
Repeated dosing is associated with counter regulation to alpha blockade and reduction in blood pressur e effects.  
Participants will be trained to recognize signs and symptoms of OH, and how to manage it should it occur.  
For the first 24 hours of dosing, participants should avoid situations in which injury might occur (eg, driving) should there be orthostati c symptoms . 
Neuroleptic malignant 
syndrome (NMS)  Observed within the class of D [ADDRESS_125012] significant  
penetrat ion of  the CNS. Nevertheless, clinical assessment for early detection of 
NMS will be  included in the study.  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  30 2.5.2. Benefit Assessment  
Patients with gastroparesis arising from diabetic or idiopathic origin may benefit from receiving 
NG101, which has the potential to alleviate the significant symptom burden associated with the 
condition. Use of metopi[INVESTIGATOR_112162] ( Vogalene Summary of Product Characteristics, 2017). In addition, 
participants may benefit from the clinical monitoring and continuation of background medications during the study. 
2.5.3. Overall Benef it: Risk  Conclusions  
Taking into account the measures taken to minimize risk to participants in this study, the 
potential risks identified in association with NG101 are justified by [CONTACT_112220]. In [LOCATION_009], metopi[INVESTIGATOR_112163], and has been prescribed for over 40 years. The 
body of evidence generated to date reflects a positive benefit risk balance in that indication. 
 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  33 PAGI- SYM  = Patient Assessment of Upper Gastrointestinal Disorders -Symptoms Questionnaire ; 
PAGI- QOL  = Patient Assessment of Upper Gastrointestinal Disorders -Quality of Life ; PGI-C = Patient Global 
Impression of Change; PGI-S = Patient Global Impression of Severity ; PD = pharmacodynamic;  
PK = pharmacokinetic ; PRO = patient -reported outcomes; TEAEs = treatment -emergent adverse events; 
TEAESIs = treatment -emergent adverse events of special interest; TESAEs = treatment -emergent serious adverse 
events.  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  34 4. Study Design  
4.1. Overall  Design  
This is a randomized, double- blind, parallel -group (4 arms), placebo- controlled, m ulticenter 
study to evaluate the safety and efficacy of 3 dose levels of NG101 compared with placebo in 
participants with diabetic or idiopathic gastroparesis.  
The total duration of the study for each participant will be approximately 20 weeks. Following a Screening Period of up to 4- weeks, eligible participants will enter a 2- week  Pretreatment Period 
during which time they will complete specified gastroparesis symptom assessments to establish 
baseline data and to determine compliance with completion of the se assessments. Following 
completion of the Pretreatment P eriod, a participant’s randomization eligibility will be 
determined (based on all inclusion/exclusion criteria, including the participant’s compliance with eDiary completion).  
Participant s who do not initially meet study screening criteria (ie, are screen failures) may be 
rescreened (no more than 1 additional Screening) after consultation with and approval by [CONTACT_103]. A p articipant’s eligibility for the study must be confirmed by [CONTACT_456] ’s Medical 
Monitor , or designee, prior to randomization.  
Participan ts eligible for the clinical study will be randomized in a 1:1:1:1 ratio to receive either 
NG101 treatment arms of 5 mg, 10 mg, or 20 mg, or matching placebo during a 12- week 
Treatment Period. Randomization will be stratified on the following factors: gastroparesis 
etiology (diabetes vs idiopathic), sex (male vs female), and current cannabinoid use (yes vs no). 
Determination of diabetes etiology will be done according to the medical history data at Screening. 
NG101  will be administered orally (PO) QID for 12 weeks. The 20 mg arm will initiate dosing 
on Day 1 with 5 mg QID for 4 days, followed by 10 mg QID for 3 days, and then 20 mg QID 
through Week 12. No titration will occur in the 5 mg and 10 mg arms. The study drug should be taken by [CONTACT_112221] 30 minutes before a meal 3 times a day and 30 minutes 
before bedtime, with a minimum interval of 4 hours between doses.  
Two weeks  following the end of treatment / Week 12 Visit, pa rticipants will return to the clinic 
for an End of  Study (EoS) Visit / Follow-up V isit.  
If a participan t permanently discontinues study medication (for any reason) prior to the 
Week  [ADDRESS_125013] attend the Early Discontinuation Visit as soon as possible, 
and then the Safety Follow-up Visit 2 weeks later.  
The sponsor wil l review blinded data on an ongoing basis. Independent reviews of safety data 
will be done if needed.    
Study Assessments:  
Study assessments will be performed at the times specified in the Schedule of Activities (S oA – 
Section 1.3 ).  
The primary efficacy objective is to determine the efficacy of NG101 to reduce nausea severity 
in participants with gastroparesis. The primary endpoint is  the change from baseline at Weeks 7 
through 12 for the nausea severity score in the Diabetic and Idiopathic Gastroparesis Symptoms 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  35 Daily Diary (DIGS -DD).  Key secondary efficacy endpoints will also be assessed by [CONTACT_112211] -DD and include changes from baseline at Weeks [ADDRESS_125014] -prandial fullness severity score, 
abdominal pain severity score , and total severity score (nausea, early satiety, post -prandia l 
fullness, abdominal pain) . An eDiary will be used to collect information for the primary and key 
secondary endpoints.  
In addition, blood samples will be obtained to measure plasma levels of metopi[INVESTIGATOR_112164] -dose adminis tration (Day 1) and at steady -state after 
multiple -dose administration (Week 2). Blood samples for PK will be collected at the Day 1 and 
Week 2 visits for all participants (up to [ADDRESS_125015] dose  on each occasion . In a subset 
of participants  (8 to 10 participants per treatment arm; 32 to 40 participants total),  intensive 
sampling will be performed (up to [ADDRESS_125016] dose at the Day 1 and Week 2 visits, as 
well as 1 and 2 hours after the second dose at the Day 1 visit ). 
4.2. Scientific Rationale for Study Design 
Patients with gastroparesis arising from either diabetic or idiopathic etiology will be enrolled in this study. Both subsets of patients may derive improvement in symptoms from D
[ADDRESS_125017]. The 12- week duration of the 
Treatment Period will enable assessment of the durability of response to treatment with metopi[INVESTIGATOR_112122].  
Dose selection for this study is based on the evaluation of a range of estimated target receptor 
(D
2) occupancies, phase 1 study results, and the cli nical experience with marketed metopi[INVESTIGATOR_112165] (see Section 4.3 ). The dose escalation in the [ADDRESS_125018] on patient quality of life (FDA 201 9). Moreover, nausea is likely to be the most 
sensitive symptom of gastroparesis to facilitate detection of a treatment effect from D
[ADDRESS_125019] been designed to balance the need to treat a participant’s symptoms and the ability to detect a treatment effect of metopi[INVESTIGATOR_112122]. Stratification factors were identified as potentially impacting the clinical course and/or treatment response, and have been 
incorporated into planned analyses. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  38 5. Study Population  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
Note : "Enrolled" means a participant, or their legally acceptable representative, agreed to 
participate in a  clinical study following completion of the informed consent process.  
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Participant must be  ≥ 18 years of age at the time of signing th e informed consent. 
Type of Participant and Disease Characteristics 
2. Participant  has a diagnosis of diabetic or idiopathic gastroparesis with:  
• Documented evidence of no mechanical obstruction, as determined by a 
gastroenterologist such as by [CONTACT_112222], and in the investigator’s opi[INVESTIGATOR_112166], 
and 
• Diagnosis and symptoms consistent with gastroparesis (eg, nausea, vomiting, early satiety, post-prandial fullness, and abdominal pain) for at least 6 consecutive months 
preceding the Screening Visit, and  
• Delayed gastric emptying of solids during the Screening Period or within [ADDRESS_125020] (demonstrating delayed gastric emptying at 4 hours) or scintigraphy 
(demonstrating ≥ 10% residual food remaining at 4 hours).  
Note:  There must be a minimum of 7 days between the gastric emptying study and 
the start of the Pretreatment Period, and  
• No known cause other than diabetes (ie, pa rticipants with gastroparesis due to other 
causes such as surgery, Parkinson’s disease, post -abdominal irradiation, atrophic 
gastritis, suspected arterial occlusion, Crohn’s disease, Chagas disease, etc., would be excluded). 
Note: A minimum of [ADDRESS_125021] 
3 months prior to the Screening Visit following either:  
• Discontinuation of the gastric stimulator, or  
• Initiation of a stable treatment regimen. The participant must agree to maintain the 
same stable treatment regimen for the duration of the clinical study.  
Neurogastrx, Inc .   NG101 -[ADDRESS_125022] all of the following during each week of the P retreatment Period on 
the DIGS -DD: 
• Sum of the mean  severity scores for each of the 4 gastroparesis symptoms ≥ 12. 
(The  4 symptoms are: nausea, early satiety, post- prandial fullness , and abdominal 
pain.) 
• A mean nausea severity score that is ≥ 4 and also greater than the mean severity score 
for abdominal pain.   
• Compliance with eDiary completion, as measured by [CONTACT_112223] 5 of 7 days of eDiary questions for each of the 2 weeks in the Pretreatment 
Period . 
5. Participant is ambulatory (eg, not bed-ridden, nursing home resident, etc.). 
6. Participant  agrees to refrain from making any major changes in diet, weight, exercise, or 
other major lifestyle patterns after signing the informed consent form (ICF) and through 
the EoS Visit . 
7. Participant must be able to independently complete PRO assessments without assistance from others . 
Sex 
8. Participant  is male or female.  
Contraceptive use by [CONTACT_19660] (WOCBP) should be consistent with 
local regulations rega rding the methods of contraception for those participating in clinical 
studies.  
Female particip ants are eligible if:  
• She is not pregnant (confirmed by [CONTACT_112224] a 
negative urine pregnancy test prior to study drug administration on Day 1) or 
breastfeeding, and  at least 1 of the following conditions applies: 
o She is not a WOCBP  as defined in Appendix 10.6), or  
o She is a WOCBP who agrees to use [ADDRESS_125023] dose of study drug. A highly 
effective method of birth control is defined as that which results in a low failure 
rate (ie, less than 1% per year) when used consistently and correctly, such as 
implants, injectable or combined oral contraceptives, patches, intrauterine devices 
(IUDs), sexual abstinence or vasectomized partner  (or partner who follows the 
specifications outlined below). 
Males participants are eligible if:  
• He is of procreative capacity (ie,  surgically sterile) or of procreative capacity and agrees 
to use an acceptable method of contraception from randomization through [ADDRESS_125024] dose of study medication. (Examples of acceptable contraception for 
Neurogastrx, Inc .   NG101 -[ADDRESS_125025]-menopausal 
partner [or partner who follows the specifications outline d above].) 
Informed  Consent  
9. Participant is capable of giving signed informed consent.  
10. Participant  has signed an ICF before any study- specific procedures are performed . 
5.2. Exclusion Criteria   
Participants are excluded from the study if any of the following criteria apply:  
Medical History  
1. Participant  has another active disorder that, in the opi[INVESTIGATOR_871], can cause 
abdominal pain or discomfort, nausea, vomiting, fullness, bloating, or other 
gastrointestinal symptoms that may confound the assessment of gastroparesis symptoms.  
2. Participant  has been hospi[INVESTIGATOR_112167] 2 months prior to the Screening Visit for 
uncontrolled diabetes mellitus, gastroparesis, or associated malnutrition.  
3. Participant  has had surgery that meets any of the fol lowing criteria:  
• Gastric surgery, including fundoplication, gastric banding, by[CONTACT_6476], resection, or 
gastric per -oral endoscopic pyloromyotomy, at any time before the Screening Visit.  
• Surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months 
before the Screening Visit.  
• An appendectomy or cholecystectomy during the 3 months before the Screening 
Visit.  
• Other major surgery during the 3 months before the Screening Visit.  
4. Participant  has evidence of unexplained recurrent dizziness or syncope within 6 months 
prior to the Screening Visit.  
5. Participant has a history of intolerance to phlebotomy, (eg, experiences dizziness or 
syncope). 
6. Female participants with a history of galactorrhea, or unexplained amenorrhea. 
7. Participant has history of or current clinically significant cardiac arrhythmia, including ventricular tachycardia, ventricular fibrillation, Torsade des Pointes, bradycardia, sinus node dysfunction, heart block, or family history prolonged QT syndrome. Pa rticipan ts 
with minor forms of ectopy (eg, premature atrial contractions) are not necessarily excluded. 
8. Significant CV events (eg, myocardial infarction, unstable angina, hospi[INVESTIGATOR_112168], cardiac surgery, ischemic or hemorrhagic stroke, or transient ischemic attack) within 6 months before the Screening visit.  
9. Participant  has a history of cance r, including prolactinoma (resected basal cell or 
squamous cell carcinoma of the skin is acceptable). Note:  Participants with a history of 
cancer are eligible provided that the malignancy has been in complete remission 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  41 (disappearance of all signs of cancer  in response to treatment) for at least 5 years before 
the Screening Visit.  
10. Participant  has a history of active alcoholism or drug addiction within 12 months prior to 
the Screening Visit.  
11. Participant engages in daily recreational use of marijuana . Note:  If pa rticipants  are 
currently using marijuana or other cannabinoids, concomitant use is allowed if it is 
considered stable over the [ADDRESS_125026]  not increase  during the 
study. Up to approximately 140 participants can  be cannabinoid use rs (see Section 9.1 ), 
and of these up to approximately 56 can be marijuana users. 
12. Urine drug screen positive for non- prescribed drugs, except cannabinoids if use is 
reported by [CONTACT_96564] t. 
13. Participan t engages in vapi[INVESTIGATOR_007]. 
14. Participant  has been hospi[INVESTIGATOR_80529] a psychiatric condition or has made a suicide 
attempt within 12 months prio r to the Screening Visit.  
15. Participant  has a history of clinically significant hypersensitivity or allergies to any of the 
excipi[INVESTIGATOR_112169] (NG101 or placebo). 
16. Participant  has an acute or chronic condition that, in the investigator’s opi[INVESTIGATOR_112170]’s opi[INVESTIGATOR_1649], would limit the pa rticipant’s ability to complete or participate in this 
clinical study.  
17. Participant has a body mass index < 18 kg/m2 or > 39 kg/m2. 
Prior  / Concomitant Therapy 
18. Participant has had endoscopic pyloric injections of botulinum toxin within the 6 months prior to the Screening Visit.  
19. Participant  has received and tolerated an adequate course (at least [ADDRESS_125027] 1 month) of treatment with domperidone and sh owed no 
notable symptomatic improvement in gastroparesis symptoms.  
20. Use prior to Screening (within the previous 14 days or 7 half-lives, whichever is longer) or intended use during the study of any prohibited medications (see Appendix 10.2).  
21. Initiation of treatment or change in dose or dose regimen within 3 months prior to the Screening Visit for any drug that prolongs QT interval. Note:  Concomitant use of drugs 
that prolong QT interval is permitted provided that the pa rticipant has been receiving the 
drug for at least 3 months, has a normal QT interval at the Screening Visit, and remains on same dose and regimen during the clinical study (see Appendix 10.2).  
22. Use of ondansetron or promethazine as an anti- emetic more than  2 times/day (total daily 
doses should not exceed 16 mg ondansetron or 50 mg promethazine). 
23. Use of anti -emetics (ie, ondansetron or promethazine) within 24 hours prior to the Day 1 
visit.  
24. Participant is receiving parenteral nutrition or using a feeding tube.  
25. Change in use of any alternative treatment (eg, acupuncture, hypnosis) from 2 weeks prior to the Screening Visit until the EoS.  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  42 26. Changes in dose or dose regimen from 30 days prior to the Screening Visit until the EoS 
visit for any chronically administered concomitant medications listed in the permitted 
medications section (see Appendix 10.2).  
Prior  / Concurrent Clinical Study Experience  
27. Current enrollment or past participation within the last 30 days before signing of consent in any other clinical study involving an investigational study treatment or device or is planning to receive another investigational intervention at any time during the study (see Appendix 10.2).  
Diagnost ic Assessments 
28. Participant has uncontrolled diabetes defined as H gbA1c > 10% at the Screening Visit.  
29. Participant has thyroid stimulating hormone (TSH) below the lower limit of normal, or above the upper limit of normal (ULN) if free T4 is below the lower limit of normal.  
30. Male participants with  serum  testosterone below the lower limit of normal at Screening.  
31. Participant has prolactin levels > [ADDRESS_125028]  
32. Participant has QTcF > 450 msec for male participan ts or QTc F > 470 msec for female 
participants, or Q TcF > 480 msec in participant s with right bundle branch block 
(participants  with left bundle branch block are excluded). 
33. Participant experiences a ny clinically significant finding on a physical exam, 12- lead 
ECG, or clinical laboratory test after signing the ICF but prior to randomization . The 
investigator will determine if a particular finding is clinically significant. In making this determination, the investigator will consider whether the particular finding could prevent the pa rticipant from performing any of the protocol- specified assessments, could 
represent a condition that would exclude the pa rticipant from the study, could represent a 
safety concern if the pa rticipant continues in the study, or could confound the 
study- specified assessments of safety or efficacy.   
Note:  By [CONTACT_108], a positive drug screen is clinically significant (with the exception of 
marijuana).  
34. Participant has severe postural symptoms and/or absolute systolic BP  < 90 mm Hg  upon 
standing. Note:  these severe symptoms include presyncope, syncope, and other severe 
AEs that are considered of substantial clinical relevance by [CONTACT_093] (see Table 3 
for additional details and definitions).  
35. Estimated glomerular filtration rate ≤ 45 mL/minute /1.73 m
2 (based on the Chronic 
Kidney Disease Epi[INVESTIGATOR_10444] [CKD- EPI] equation; s ee Appendix 10.7). 
36. Aspartate aminotransferase or alanine aminotransferase > [ADDRESS_125029]; alkaline phosphatase or bilirubin >1.[ADDRESS_125030] (isolated bilirubin >1.[ADDRESS_125031] bilirubin < 35%).  
Other Exclusions 
37. Donation of blood or blood loss > 400 mL within 90 days prior to the Screening Visit.  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  43 5.3. Lifestyle Considerations  
No restrictions to lifestyle considerations are required for this study. However, as indicated in 
Secti on 5.1 (inclusion criterion 6) , participants must agree to refrain from making any major 
changes in diet, weight, exercise, or other major lifestyle patterns after signing the ICF and 
through the EoS Visit. 
5.3.1. Meals and Dietary Restrictions  
Refrain from consumption of Seville oranges, grapefruit or grapefruit juice  for a minimum of 
7 days prior to  start ing study drug until after the final dose . 
The study drug should be taken by [CONTACT_112221] 30 minutes before a meal 3 times a 
day and 30 minutes before bedtime, with a minimum interval of 4 hours between doses. 
Day 1 and Week 2 Visits: 
For the Day 1 and Week 2 PK assessment s, participants who are not in the Intensive PK Subset 
should arrive at the clinic in the morning after fasting (water is allowed) for at least [ADDRESS_125032] dose of study drug of the 
day. (See also Section  8.7.1.)  
For the Day 1 and Week 2 PK assessment s in the Intensive PK Subset, participants should arrive 
at the clinic in the morning after fasting (water is allowed) for at least [ADDRESS_125033] dose of study drug of the day. (See also Section  8.7.1.) 
At the Day [ADDRESS_125034] dose should be administered with 240 mL of water. No 
additional water is permitted  until 30 minutes after dosing, after which time, water is allowed ad 
libitum.  
5.3.2. Caffeine, Alcohol, and Tobacco 
The intake of alcohol, caffeine  and tobacco  should not be increased during the study. 
5.3.3. Activity  
No study- specific activity restrictions apply , except to refrain fro m making any major changes in 
diet, weight, exercise, or other major lifestyle patterns after signing the ICF and through the EoS Visit.  
5.4. Screen Failures  
Screen failures are defined as participant s who consent to participate in the clinical study but are 
not subsequently entered in the study. A minimal set of screen failure information is required to ensure transparent reporting of screen failure participant s to meet the Consolidated Standards of 
Reporting Trials  publishing requirements and to respond to queries from regulatory authorities. 
Minimal information includes demography, reason for screen failure, and any serious adverse 
event ( SAE ). 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  44 Participants who do not initially meet study Screening criteria (ie, are screen failures) may be re -
screened (no more than 1 additional Screening) after consultation with and approval by [CONTACT_112225]. 
5.5. Pretreatment Period Failures  
Pretreatment failures are defined as participants wh o do not meet the prespecified criteria for 
eligibility regarding the Pretreatment Period assessments  (see Section 5.1, inclusion criterion 4).  
Participants who are pretreatment failures may be  re-screened  upon approval from the sponsor 
and/or Medical Monitor or designee. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  45 6. Study Drug 
Study drug is defined as an y investigational intervention (s), marketed product(s), placebo, or 
medical device(s)  intended to be administered to a study participant according to the study 
protocol. 
6.1. Study Drug (s) Administered  
The study drugs planned for use are described in Table 1 below:  
Table 1: Study Drug s 
Arm Name  [INVESTIGATOR_1645]101 5 mg Arm NG101 10 mg Arm NG101 20 mg Arm Placebo Arm  
Intervention 
Name  [CONTACT_112252][INVESTIGATOR_112171](s)  NG101 5 mg, QID  NG101 10 mg, QID  NG101 20 mg, QID  Placebo, QID  
Route of 
Administration Oral Oral Oral Oral 
Use Experimental  Experimental  Experimental  Placebo 
comparator  
IMP and NIMP  IMP  IMP  IMP  NIMP  
Sourcing  Provided by [CONTACT_112226]101 5 mg 
capsules will be provided in a blister pack  
labeled as required 
per country 
requirement  NG101 10 mg capsules will be provided in a blister pack labeled as required per 
country 
requirement  NG101 20 mg capsules will be provided in a blister pack labeled as required per country requirement  Placebo capsules will be provided in a blister pack labeled as required per 
country 
requirement  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  46 Study drug will be dispensed at each visit duri ng the Treatment Period. Each participant will also 
be dispensed an extra blister pack in case dispensed study drug becomes depleted. Participants 
will be required to return for clinic visits with all dispensed medication (ie, study drug and rescue medicat ion) to ensure use is recorded properly. Note that during the following visits, study drug 
will be administered in the clinic:  
• Day 1:  first dose in the clinic, and second dose of the day in the clinic for those 
participants in the Intense PK subset  
• Week 1:  a dose in the clinic (ie, not necessarily the first dose of the day)  
• Week 2:  first dose of the day in the clinic 
• Week 12:  a dose in the clinic (ie, not necessarily the first dose of the day)  
All study drug capsules will be identical in appearance in order to maintain the blind. 
Participan ts in the 20 mg treatment arm will be titrated up to the target dose in a blinded fashion. 
Specifically, the 20 mg arm initiation blister pack will contain a 4 -day supply of 5 mg QID, and a 
3-day supply of 10 mg QID, after which the blister packs will contain a 7 -day supply of 20 mg 
QID. (Note: For participants in the placebo, 5 mg, or 10 mg arms, the blister pack will contain 
only the assigned treatment doses.)  
If a dose is missed, (eg, not taken by [CONTACT_2669] 1 hour after a meal), then participants should skip 
the missed dose and resume dosing with the next planned dose (30 minutes before the next meal 
or before bedtime).   
6.2. Preparation / Handling / Storage  / Accountability  
The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study drug received and any discrepancies are reported and resolved before use of the study drug. 
Only participants enrolled in the study may receive study drug  and only authorized site staff may 
supply or administer study drug. All study drug must be stored in a secure, environmentally 
controlled, and monitored (manual or automated) area in accordance with the labeled stor age 
conditions with access limited to the investigator and authorized site staff.  
The study drug will be shipped with a temperature monitor and under ambient storage 
conditions. 
The investigator, institution, or the head of the medical institution (where a pplicable) is 
responsible for study drug accountability, reconciliation, and record maintenance (ie, receipt, 
reconciliation, and final disposition records).  
Further guidance and information for the final disposition of unused study drug s are provided in 
the Pharmacy Manual.  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  47 6.3. Measures to Minimize Bias: Randomization and Blinding  
Participants eligible to participate in the clinical study will be randomized in a 1:1:1:1 ratio to 
receive either NG101 treatment arms of 5 mg, 10 mg, or 20 mg, or matching placebo. Randomization will be stratified on the following factors: gastroparesis etiology (diabetes vs 
idiopathic), sex (male vs female), and cannabinoid use (yes vs no). Determination of diabetes 
etiology will be done according to the medical history data at Screening. 
All participants will be centrally assigned to randomized study drug using interactive response 
technologies (IRT ). Before the study is initiated, the log in information and directions for the 
IRT will be provided to each site.  
Study drug will be  dispensed at the study visits summarized in the SoA.  
Returned study drug should not be re-dispensed to the participants. 
Blind Break:  
The IRT  will be programmed with blind -breaking instructions. In case of an emergency, the 
investigator has the sole resp onsibility for determining if unblinding of a participants’ 
intervention assignment is warranted. Participant safety must always be the first consideration in 
making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every effort to contact [CONTACT_456] ’s medical monitor or designee  prior 
to unblinding a participant’s intervention assignment unless this could delay emergency 
treatment of the participant. If a participant’s intervention assignment is unblinded, the sponsor 
must be notified within [ADDRESS_125035] be recorded in the source documentation and case report form (CRF) , as applicable. 
6.4. Study Compliance  
Compliance with completing study visits and assessments per protocol will be assessed throughout the study.  
Compliance with completing daily diaries during the Pretreatment Period and the Treatment 
Period will also be assessed.  
When participants are dosed at the site (Day 1 , Week 1 and Week 2) , they will receive study 
drug under medical supervision. The date and time of each dose administered in the clinic will be recorded in the source documents and recorded in the CRF.  
Compliance with study drug will be assessed at each visit. Compliance will be assessed by 
[CONTACT_112227]. Deviation(s) from the prescribed dosage regimen should be recorded in the eCRF.  A record 
of the number of capsules dispensed to and taken by [CONTACT_112228]. Intervention start and stop dates, including 
dates for intervention delays and/or dose reductions will also be recorded in the CRF. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  48 6.5. Concomitant Therapy  
Any medication or vaccine (including over- the-counter or prescription medicines, v itamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or receives 
during the study must be recorded along with: 
• Reason for use 
• Dates of administration including start and end dates  
• Dosage information including dose and frequency 
The Medical Monitor should be contact[CONTACT_31182]. 
The prohibited medications indicated in Appendix 10.2 are excluded within the previous 14 days 
or 7 half- lives (whichever is longer) before the Screening Visit.  
Participants should be on a stable dose of permitted concomitant medications, as indicated in 
Appendix 10.2, including herbal treatments, for at least 30 days prior to the Screening Visit. 
Participants should intend to maintain their usual medication regimen throughout the study.  
6.5.1. Rescue Medicine  
The study site will supply anti- emetic  rescue medication that will be provided by [CONTACT_456]. 
The following rescue medications may be used: 
• Ondansetron (4 mg tablet )  
• Promethazine (25 mg  tablet )  
The use of rescue medications is allowed  up to 2 times daily  during the P retreatment Period and 
the T reatment Period, except on the day prior to (within 24 hours) and the day of clinic visits.  
Participants will be instructed to use rescue medication only during a day when nausea or vomiting is intolerable. For participants taking ondansetron, a second [ADDRESS_125036] dose if there has been insufficient relief of n ausea; thus, participants are 
allowed up to 4 tablets (16 mg) per day.  
Participants are required to use only the study- provided rescue medications.  Use of rescue 
medication will be captured in the daily diary; compliance with regard to rescue medication w ill 
be assessed at each study visit and captured in the source documents.  As described in 
Section  9.3.4, weekly use of rescue medication will also be assessed as an additional secondary 
endpoint. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  49 6.6. Dose Modification  
Participan ts will receive either NG101 5, 10 or 20 mg QID or matching placebo QID for 
12 weeks. Participan ts in the 20 mg treatment arm will be titrated up to the target dose in a 
blinded f ashion. 
Dose modification is not permitted; however, if deemed medically necessary, study medication 
may be temporarily interrupted and restarted after consultation with the Medical Monitor or 
designee. See Section 7.1.1. 
6.7. Intervention after the End of the Study  
No extension study is planned. 
Upon completing the Treatment Period or End of Treatment / Early Termination Visit, 
participants should be treated according to the local standard of care.  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  50 7. Discontinuation of Study Drug  and Participant 
Discontinuation / Withdrawal  
7.1. Discontinuation of Study Drug 
In rare instances, it may be necessary for a participant to permanently discontinue (definitive 
discontinuation) study drug . If study drug is definitively discontinued, the participant will remain 
in the study to be evaluated for follow -up.  
If a clinicall y significant finding i n clinical laboratory or ECG parameters is identified 
(including, but not limited to changes from baseline in QT interval corrected using Fridericia’s 
formula [QTcF] after enrollment ), the investigator or qualified designee will determine if the 
participant  can continue in the study and if any change s in participant management are  needed . 
This review of the ECG printed at the time of collection  must be documented. Any new 
clinically relevant finding should be reported as an AE.  
For any female participants, or partners of male participants, who become pregnant during the 
study, see guidance in Appendix 10.6. 
See the SoA for data to be collected at the time of discontinuation of study drug and follow-up, and for any further evaluations that need to be completed ( Section 1.3 ). 
Criteria for Withdrawal from Treatment : 
• AE(s) which, in the opi[INVESTIGATOR_26335], make continued treatment in 
the study inappropriate  
• AEs consistent with EPS, such as acute dyskinesias and dystonic reactions, tardive 
dyskinesia, Parkinsonism, akinesia, or akathisia.  
• Neurolepti c malignant syndrome .  
• Worsening of gastroparesis signs and/or symptoms that cannot be adequately controlled by [CONTACT_2299]’s current treatment regimen (including the protocol- allowed rescue 
treatment), and thus make continued treatment in the study in appropriate.  
• Significant non- compliance  
• Withdrawal of consent to receive the study treatment  
• Orthostatic hypotension (decrease in systolic BP of at least 20 mm Hg) with associated severe postural symptoms (including presyncope, syncope, and other severe AEs that 
are considered of substantial clinical relevance by [CONTACT_093]). See Table [ADDRESS_125037] 
be interrupted for longer than 3 days, consult the Medical Monitor about the participant’s 
continuation in the study. If this temporary interruption is due to an AE, this should be indicated as an outcome of the AE in the CRF. 
7.1.2. Reinitiation  
Reinitiation of study drug after interruptions of at least  [ADDRESS_125038] 3 days 
will reinitiate dosing using a blinded initiation blister pack .  
Since partic ipants in the 20 mg treatment arm will initially titrate up to the targeted dose of 
20 mg, all participants in this arm who temporarily interrupt study drug will reinitiate dosing via 
titration beginning with 5 mg QID. Specifically, the 20 mg arm reinitiat ion blister pack will 
contain a 4-day supply of 5 mg QID, and a 3-day supply of 10 mg QID. (Note: For participants 
in the placebo, 5 mg, or 10 mg arms, the blister pack will contain only the assigned treatment doses.) 
7.2. Participant Discontinuation / Withdrawal from the Study  
A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral , compliance, or 
administrative reasons. This is expected to be uncommon. 
At the time of discontinuing from the study, if possible, an early discontinuation visit should be 
conducted, as shown in the SoA ( Section 1.3). The participant will be permanently discontinued 
both from the study drug and from the study at that time.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent. If a participant 
withdraws from the study, he/she may request destruction of any samples taken and not tested, 
the investigator must document this in the site study  records , and the sponsor representative 
should be notified. 
Participants who either complete the Treatment Period or have an Early Discontinuation visit 
should be treated according to the local standard of care. However, if possible, prohibited medications should be avoided during the 2-week Follow up Period. 
Criteria for Withdrawal from Study  
• Withdrawal of consent to participate in the study  
• Lost to follow up (despi[INVESTIGATOR_112172] ) 
• Death  
Neurogastrx, Inc .   NG101 -[ADDRESS_125039] to follow -up if he /she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298]. 
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:  
• The site must attempt to contact [CONTACT_47995] m issed visit as soon 
as possible and counsel the participant on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the participant wishes to and/or should 
continue in the study. 
• Before a participant is deemed lost to follow up, the investigator or designee must make 
every effort to regain contact [CONTACT_6635]  (where possible, 3 telephone calls and, 
if necessary , a certified letter to the pa rticipant’s last known mailing address or local 
equivalent methods). These contact [CONTACT_13140]’s 
medical record . 
• Should the participant  continue to be unreachable, he/she will be considered to have 
withdrawn from the study .  
Discontinuation of specific sites or of the study as a whole are handled as part of 
Appendix 10.1.9. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  53 8. Study Assessments and Procedures 
Study procedures and their timing are summarized in the SoA ( Section 1.3 ). Protocol waivers or 
exemptions are not allowed. Adherence to the study design requirements, including those 
specified in the SoA, is essential and required for study conduct. 
All S creening evaluations must be completed and reviewed to confirm that potential participants 
meet all eligibility criteria. T he investigator will maintain a screening log to record details of all 
participant s screened and to confirm eligibility or record reasons for screening failure, as 
applicable. Procedures conducted as part of the participant’s routine clinical management (e g, 
blood count) and obtained before signing of the ICF may be utilized for screening or baseline 
purposes provided the procedures met the protocol- specified criteria and were performed within 
the time frame defined in the SoA . 
Immediate safety concerns sho uld be discussed with the sponsor immediately upon occurrence or 
awareness to determine if the participant should continue or discontinue study drug. 
When several procedures are scheduled at the same theoretical time and/or visit, in general the study asse ssments should be performed in the following order: 
• PRO assessments  
• 12-lead ECG  
• Vital signs  
• Blood samples 
8.1. Total Volume of Blood  
The maximum amount of blood collected from each participant over the duration of the study, including any extra assessments that may be required, will not exceed 224 mL  (Table 2). Repeat 
or unscheduled samples may be taken for safety reasons, or for technical issues with the samples. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  54 Table 2: Total Volume of Blood Required for Each Assay 
Assay  Number of samples  Volume per sample 
(mL) Total  
volume (mL)  
Males Females  
Optional genetic testing 
sample  [ADDRESS_125040] (females only) 1 2 -- 2 
HgbA1c  4 1 4 4 
Thyroid stimulating hormone (TSH)  1 3 3 3 
Serum testosterone  
(males only)  1 0.5 0.5 -- 
Serum prolactin     
All participants  8 2 16 16 
Intensive PK subset  14 2 28 28 
Serology  
1 8 8 8 Hepatitis B surface antigen  
Hepatitis C antibody  
Hepatitis C viral load RNA  
HIV 1 and 2 antibody  
Geenius HIV 1/2 
differentiation 
Hematology  9 2 18 18 
Serum chemistry  9 4 36 36 
PK blood sample collection  
Sparse PK  
(all participants)  8 6 48 48 
Intensive PK Subset  20 6 120 120 
 Total Volume - Sparse PK (all participants)  138.[ADDRESS_125041] (GEBT), to be used with the GEBT test meal, is intended for 
use in the measurement of the rate of gastric emptying of solids and as an aid in the diagnosis of delayed gastric emptying (gastroparesis) i n adult humans who are symptomatic for gastroparesis 
(GEBT S ummary of Safety and Effectiveness,  2015). The GEBT is a non -radioactive, non-
invasive, orally administered test for measurement of the rate of solid phase gastric emptying in adults. The GEBT has been validated against the reference method of gastric scintigraphy. The 
GEBT utilizes the stable isotope carbon -13 (
13C). The GEBT measures how fast the stomach 
empties solids after ingestion of a cooked egg test meal, labeled with 13C-Spi[INVESTIGATOR_112173] s. The 
GEBT may be administered in a primary care facility, clinic or tertiary care setting.  
The GEBT procedure is conducted over a 4- hour period. Following an overnight (or ≥  8 hour) 
fast, duplicate pre -meal breath samples are collected from the participant  (used to establish a 
participant’s baseline 13CO 2 level). Following pre- meal breath sample collection, the participant  
is administered the test meal. Single post- meal breath  samples are subsequently collected at 45, 
90, 120, 150, 180, and [ADDRESS_125042] meal administration  and are analyzed  by [CONTACT_112229] r atio m ass spectr ometry to determine the ratio of 13CO 2/12CO 2 in each sample. By 
[CONTACT_112230]- meal value, the rate of 13CO 2 
excretion can be calculated and the individual’s gastric emptying rate determined. 
Contraindications 
Individuals with known hypersensitivity to Spi[INVESTIGATOR_112174], egg, milk or wheat allergens should avoid 
the GEBT  (GEBT Summary of Safety and Effectiveness,  2015).  
Because the GEBT is an indirect multi -compartmental method of measuring gastric  emptying, 
GEBT results may be inaccurate in individuals compromised with significant small bowel, pancreatic, liver and/or lung disease. Consequently, the GEBT should not be administered to 
patients with pulmonary dysfunction (eg, COPD) and/or small bowel malabsorption. 
8.3. Efficacy Assessments  
Planned time points for all efficacy assessments are provided in the SoA ( Section 1.3 ). 
8.3.1. Diabetic and Idiopathic Gastroparesis Symptoms Daily Diary  (DIGS -DD) 
Participants will be required to complete the Diabetic and Idiopathic Gastroparesis Symptoms daily diary (DIGS -DD) to record daily symptoms of gastroparesis . The DIGS -DD consists of 
[ADDRESS_125043] the number of times they vomited/threw up in the 
past 24-hours , and rate their vomiting severity .  
A summary of the questions included in the DIGS-DD is provided in Appendix 10.4. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  56 [IP_ADDRESS]. Gastroparesis - Additional Daily Assessments  
Additional assessments related to the DIGS -DD will be conducted to fully assess the symptoms 
of gastroparesis. These questions will assess the previous [ADDRESS_125044] of nausea on the participant’s life, and the number of hours of 
abdominal pain, feeling of fullness, and abdominal bloating. 
8.3.2. Gastroparesi s Cardinal Symptom Index Daily Diary (GCSI -DD) 
The American Neurogastroenterology and Motility Society’s  Gastroparesis Cardinal Symptom 
Index Daily Diary (GCSI- DD) is designed to assess gastrointestinal symptoms associated with 
idiopathic or diabetic gastr oparesis ( Revicki et al. 2018; Parkman et al. 2018). The instrument 
asks participants to rate the severity of 4  symptoms: nausea, inability to finish a normal -sized 
meal (ie, early satiety), feeling excessively full after meals (ie, post-prandial fullness), and upper 
abdominal pain. The severity response is rated by [CONTACT_112231] 24 hours, using a 5-point scale (none, mild, moderate, severe, very 
severe). For vomiting, the number of vomiting epi[INVESTIGATOR_1841] (emesis) over the last [ADDRESS_125045] a participant’s 
condition. 
8.3.3. Patient Assessment of Upper Gastrointestinal Disorders - Symptoms 
Questionnaire  
The Patient Assessment of Upper Gastrointestinal Disorders (PAGI)- Symptoms (SYM) 
questionnaire will be assessed during the Treatment Period (with the exception of Week 1) and at the Early Discontinuation and End of Study visits. The PAGI- SYM is intended to cover the main 
symptom groupi[INVESTIGATOR_112175]: gastroesophageal reflux disease, dyspepsia, and gastroparesis, for application in clinical trials and other studies (Rentz  et al. 2004). 
The PAGI -SYM contains 20 items and 6 subscales covering heartburn/regurgitation (7 items), 
nausea/vomiting (3 items), post- prandial fullness/early satiety (4 items), bloating (2  items), upper 
abdominal pain (2 items ), and lower abdominal pain (2 items). A 6- point Likert response scale, 
ranging from 0 (none) to 5 (very severe), is used for rating the severity of each symptom item over a 2-week recall period. 
8.3.4. Patient Assessment of Upper Gastrointestinal Disorders - Qual ity of Life 
Questionnaire  
The PAGI - quality of life (QOL) questionnaire will be assessed during the Treatment Period 
(with the exception of Week 1) and at the Early Discontinuation and End of Study visits. The 
PAGI -QOL was designed to comprehensively measure QOL outcomes for patients with upper 
GI disorders (de la Loge et al. 2004 ). 
The PAGI -QOL consists of 30 items each having a 6 -point Likert -type scale and five 
dimensions: Daily Activities (DAC; 10 items related to avoiding or having difficulties in 
performing DAC), Clothing (CLO; 2 items, one related to feeling constricted and 1 to the frustration felt about not being able to dress as wanted), Diet and Food Habits (DIE; 7 items 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  57 related to restrictions made and induced frustration), Relationship (REL; [ADDRESS_125046] of the disease on relationships with partner, relatives and friends), and Psychological 
Well -Being and Distress (PSY; [ADDRESS_125047] of the disease on feelings or emotional 
state).  
8.3.5. Nausea Profile  
The nausea profile (NP) will be assessed during the Treatment Period (with the exception of 
Week 1) and at the Early Discontinuation and End of Study visits. The NP is a subjective symptom checklist with the goal of obtaining a more in -depth description of what patients are 
experiencing when they report the feeling of nausea ( Muth  1996).  
The NP self -reported instrument will be administered to evaluate participants ’ nausea over time. 
The NP evaluates 17 descriptors of nausea across 3 subscales (somatic distress, gastrointestinal 
distress, and emotional distress) and overall. Scores for each descriptor range from 0 -9, where 
0 indicates that the participants  felt the nausea descriptor (eg, shaky) ‘not at all’ and 9 indicates 
that the participants  felt the nausea descriptor (eg, shaky) ‘severely’. The NP was validated 
against a Visual Analog Scale measure of nausea ( Muth 1996) and has been adapted for use in 
patients with  gastroparesis ( Jaffe 2011).  
8.3.6. Patient Global Impression of Severity Questionnaire  
The P atient Globa l Impression of S everity (PGI-S ) questionnaire will be assessed weekly using  a 
5-point Likert rating scale as an anchor- based approach to estimate the severity of the 
participants ’ condition. The responses to this participants -completed scale range from 0 = no 
signs and symptoms; to 4 = very severe.  
8.3.7. Patient Global Impression of Change Questionnaire  
The P atient Global Impression of Change (PGI-C) questionnaire will be assessed weekly using a 
5-point Likert rating scale as an anchor- based approach to estimate meaningful change in a 
participant ’s condition. The responses to this participant-completed scale range from 0 = no signs 
and symptoms; to 4 = very severe. 
8.3.8. Treatment Satisfaction Assessm ent 
Treatment satisfaction will be assessed weekly  using a 5- point Likert rating scale to determine  
how satisfied the participant is with the study medication’s ability to relieve  symptoms  
(Chey  et al. 2014). The responses to this participant- completed scale range from 1 = not a t all 
satisfied, to 5 = very satisfied.   
8.3.9. Nausea Improvement  
The Nausea Improvement assessment is a 5 -category response scale asking  whether the 
participant experienced any improvement in nausea symptoms over the course of the study and, 
if so, the level of importance .  
This assessment will be conducted as an End of Study assessment.  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  58 8.4. Safety Assessments  
Planned time points for all safety assessments are provided in the SoA ( Section 1.3 ). 
8.4.1. Physical Examinations 
A complete physical exam, including neurologic, cardiovascular, pulmonary, abdominal and 
breast exams, will be performed at Screening, Day 1, and Weeks 4, 8, and 12 as well as at the Follow- up Visit.  Weight will be measured at all visits. Height (without shoes) will also be 
measured and recorded  on Day 1. Investigators should pay special attention to clinical signs 
related to previous serious illne sses. For female participants, menstrual cycle will be recorded 
during the study. 
Only clinically significant changes in physical examination findings will be recorded at 
subsequent visits, as indicated in the SoA ( Section 1.3).  
8.4.2. Vital Signs  
Vital signs, including o ral temperature, pulse rate, respi[INVESTIGATOR_697], and BP  will be measured at 
each study visit while the participant is in the sitting position. A standardized oscillometric automated BP device will be used; manual auscultatory assessment will be used only if the BP reading cannot be captured by [CONTACT_112232] (eg, based on specific 
physiologic condition, or if the  auto mated device is not functional). Blood pressure and pulse 
measurements should be preceded by [CONTACT_2669] [ADDRESS_125048] for the participant in a quiet 
setting without distractions (eg, television, cell phones). Additional information regarding the 
standard ized automated office BP assessment will be outlined in the training manual provided by 
[CONTACT_112233].  
Orthostatic vital signs will be assessed as follows (and as clinically indicated; see also the SoA  in 
Section 1.3 ).  
• At Screening, BP  and hear t rate  will be measured while sitting and after 1  minute in the 
standing position. 
• At the Day 1 V isit, BP  and hear t rate  will be measured before dosing and at 1, 2, and 
3 hours after dosing. Measurements will be done while  the participant is  sitting , as well 
as after  1 min ute in the standing position.    
• At the Week 1 Visit, BP and heart rate should be measured before dosing and at 1 hour 
after dosing. Measurements will be done while the participant is sitting, as well as after 1 minute in the standing position. 
• At the  Week 2 visit, BP  and heart rate will be measured  before dosing, and at 1, 2, and 
3 hours after dosing. Measurements will be done while the participant is sitting , as well 
as after 1 min ute in the standing position.  
For participants in the Intensive PK subset , in addition to the assessment s described above, 
orthostatic vit al signs will also be assessed at the  Day 1 and Week 2 visits  at hours 4, 5, and 6, as 
well as 1 and 2 hours after the second dose in the clinic on Day 1. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  59 8.4.3. Electrocardiograms  
Triplicate 12 -lead ECG s will be obtained as outlined in the SoA (see Section  1.3) using an ECG 
machine that automatically calculates the heart rate and measures PR, QRS, QT, and  QTc F 
intervals.  
At each time point at which triplic ate ECG are required, [ADDRESS_125049] be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless judged 
by [CONTACT_112234].  
All laboratory tests with values considered clinically significantly abnormal during participation 
in the study should be repeated until the values return to normal or baseline or are no longer 
considered clinically significant by [CONTACT_10982]  
• If such values do not return to normal/baseline within a period of time judged 
reasonable by [CONTACT_093], the etiology should be identified, and the sponsor notified. 
• All protocol -required laboratory assessments, as defined in Appendix 10.3, must be 
conducted in accordance with the laboratory manual and the SoA. 
• If laboratory values from non-protocol specified laboratory assessments performed at the institution’s local laboratory require a change in participant management or are 
considered clinically significant by [CONTACT_093] (eg, SAE or AE or dose 
modification ), then the resul ts must be recorded in the CRF.  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  60 8.5. Adverse Events and Serious Adverse Events 
AEs will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally authorized representative).  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the study drug or study procedures, or that caused the participant to discontinue the study drug (see Section 7 ). 
8.5.1. Time Period and Frequency for Collecting AE and SAE Information 
All AEs and SAEs will be collected starting after the ICF is signed  until the End of Study / 
Follow- up Visit as specified in the SoA ( Section  1.3).  
All SAEs will be recorded and reported to the sponsor or designee immediately and under no circumstance should this exceed 24 hours, as indicated in Appendix 10.5.4 . The investigator will 
submit any updated SAE data to the sponsor within 24 hours of it being available.  
Investigators are not obligated to actively seek AE or SAE after conclusion of the study participation . However, if the investigator learns of any SAE, including a death, at any time after 
a participant has been discharged from the study, and he/she considers the event to be reasonably related to the study drug or study participation, the investigator must promptly notify the 
sponsor. 
8.5.2. Method of Detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 10.5. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences. 
8.5.3. Follow- up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits / contacts. All AEs considered related to study drug, SAEs, (and AEs of 
special interest , as defined in Section  8.5.7), will be followed until resolution, stabilization, the 
event is otherwise explained, or the participant is lost to follow -up (as defined in Sec tion 7.3). 
Further information on follow -up procedures is provided in Appendix 10.5.3. 
8.5.4. Regulatory Reporting Requirements for SAEs 
Prompt notification by [CONTACT_11012] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study 
drug under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study drug  under clinical investigation. The sponsor 
will comply with country -specific regulatory requirements relating to safety reporting  to the 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  61 regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), 
and investigators. 
For all studies except those utilizing medical devices investigator safety reports must be prepared 
for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local regulatory 
requirements and sponsor policy and forwarded by [CONTACT_456] (or designee) to investigators as 
necessary.  
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information (eg, summary or listing of SAEs) from the sponsor will review and then file it 
along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.  
8.5.5. Pregnancy  
Details of all pregnancies in female participants and  female partners of male participants will be 
collected after the start of study drug and the participant will be followed until the outcome of 
the pregnancy is known. 
If a pregnancy is reported, the investigator should inform the sponsor within 24 hours of learning 
of the pregnancy and should follow the procedures outlined in Appendix 10.6. 
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.  
8.5.6. Disease- Related Events and/or Disease- Related Outcomes Not Qualifying as AEs 
or SAEs  
Worsening of gastroparesis will not be considered an AE since it is captured by [CONTACT_112235]. However, the signs, symptoms, and / or clinical sequelae resulting from worsening 
of disease will be reported as an SAE if the definition of an SAE  is fulfilled, or if they are 
considered by [CONTACT_112236]- specified 
disease -related assessments ( see Appendix 10.5.1  and Appendix 10.5.2, respectively) . 
Neurogastrx, Inc .   NG101 -[ADDRESS_125050]  
Treatment -emergent AESIs are based on the known effects of D 2 and alpha-1 antagonists , as 
well as observations in the nonclinical and phase 1 studies. The rationale for inclusion of each 
TEAESI is provided in Table 3 below: 
Table 3: Adverse Events of Special Interest: Rationale for Inclusion and Criteria for 
Diagnosis 
AESI  Rationale and Criteria for Diagnosis 
Gynecomastia  Rationale:  Effects of treatment with NG101 in animals were consistent with 
the non-CNS effects seen with other D 2 antagonists. These are considered 
secondary to increased prolactin levels resulting from D 2 receptor antagonism.  
Criteria for diagnosis: Per the opi[INVESTIGATOR_80021].  Galactorrhea  
Menstrual 
irregularity  
Decreased libido  
Impotence  
Extrapyramidal symptoms (E PS) Rationale:  Although metopi[INVESTIGATOR_112176], 
AEs from central D
2 blockade may include events of EPS.  
Criteria for diagnosis: Extrapyramidal symptoms can include events 
categorized as acute (dystonia, akathisia and parkinsonism) or  tardive (tardive 
dyskinesia and tardive dystonia ; Pi[INVESTIGATOR_11958] 2005). 
Neuroleptic malignant 
syndrome (N MS) Rationale:  Although metopi[INVESTIGATOR_112176], 
AEs from central D 2 blockade may include events of NMS.  
Criteria for diagnosis: Neuroleptic malignant syndrome is considered in 
cases with  recent dopamine antagonist exposure, or dopamine agonist  
withdrawal . Clinical features include  hyperthermia; rigidity; mental status 
alteration; creatine kinase elevation; sympathetic nervous system lability; tachycardia plus tachypnea; and a negative work -up for other causes.  
The following are critical values for quantitative criteria ( Gurrera et al. 2011): 
hyperthermia, > 100.4°F or > 38.0°C on at least 2 occasions; creatine kinase 
elevation, at least [ADDRESS_125051]; blood pressure elevation ≥  25% above baseline; 
blood pressure fluctuation, ≥  20 mm Hg (diastolic) or ≥ 25 mm Hg (systolic) 
change within 24 hours; tachycardia, ≥ 25% above baseline; and tachypnea, 
≥ 50% above baseline.  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  63 Orthostatic 
hypotension (OH)  Rationale : OH was observed in phase 1 studies, and likely occurs due to 
partial inhibition of α- 1 receptors.  
Criteria for diagnosis: OH is defined by a decrease in systolic BP of at least 
20 mm Hg, and/or decrease in diastolic BP of at least 10 mm Hg, with 
associated severe postural symptoms.  
Postural AEs can include feelings of lightheadedness, general weakness, 
warmth, diaphoresis, nausea, palpi[INVESTIGATOR_112177] 
(Whitledge  et al. 2019). S evere postural symptoms include presyncope, 
syncope, and other severe AEs that are considered of substantial clinical relevance by [CONTACT_093]. Presyncope is defined as “feeling like one was going to pass out but without actual loss of consciousness” 
(Whitledge  et al. 2019). Syncope is “the sudden loss of consciousness, 
associated with inability to maintain postural tone, with immediate and 
spontaneous recovery without requiring electrical or chemical cardioversion” (da Silva  2014). 
Abbreviations: AE = adverse event; AESI = adverse event of special interest; BP = blood pressure; CNS = central 
nervous system; D 2 = dopamine receptor; E PS = extrapyramidal symptoms; NMS = neuroleptic malignant 
syndrome; OH = orthostatic hypotension; ULN = upper limit of normal.  
8.6. Treatment of Overdose  
For this study, participants are expected to take no more than  4 capsules in 1 day. 
In the event of an overdose, participants should notify the investigator and the investigator 
should: 
1. Contact [CONTACT_27465].  
2. Continue to monitor the participant for any AE  / SAE and laboratory abnormalities  
3. Document the quantity of the excess dose. 
4. Consider skippi[INVESTIGATOR_112178]101. NG101  can be reinitiated, with the timing 
depending on the amount of overdose and considering the half- life of metopi[INVESTIGATOR_112122] 
(approximately 2 hours). Reinitiation should be discussed with the medical monitor. 
Participants should be treated according to the symptoms they are experiencing. If a participant 
has symptoms suggestive of orthostasis, then the participant should sit down or lie down, 
depending on the severity of symptoms. Participants will be trained to recognize the signs and symptoms of OH. 
Decisions regarding dose interruptions or modifications will be made by [CONTACT_112237] c linical evaluation of the participant.  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  64 8.7. Pharmacokinetics  
Pharmacokinetic data collected in this study will  be analyzed according to a separate PK 
Analysis Plan and reported separately from the primary study results. 
As noted in Section 8, when several proc edures are scheduled at the same theoretical time and/or 
visit, study assessments should be performed in the following order: PRO assessments; 12- lead 
ECG; vital signs; blood samples.  
8.7.1. Pharmacokinetic Assessment Methods and Timing   
All participant s will par ticipate in PK assessment. A subset of participant s who consent will 
participate in intensive PK sampling. The timing of blood sample collections is provided in 
Table 4 below . 
At the Day 1 and Week 2 visits, participants should arrive at the clinic after fasting (see 
Section  5.3.1 for further details). Participants may have water during the fasting period, but no 
food should be consumed. Study drug should be taken 30 minutes before eating, at which point 240 mL of water should be provided with the dose. N o additional water is permitted until 
30 minutes after dosing, after which time, water is allowed ad libitum and a meal will be consumed. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  65 Table 4: Pharmacokinetic Sampling Times  
Study Day  Sparse PK  Intensive PK Subset  
PK Sample Timepoint  
(Hours after dose)  
(± Time window)  PK Sample Timepoint  
(Hours after dose)  
(± Time window)  
Day 1  Predosea Predosea 
 -- 0.5 hours (± 5 minutes)  
 1 hour (± 5 minutes)  1 hour (± 5 minutes)  
 -- 1.5 hours (± 5 minutes)  
 2 hours (± 10 minutes)  2 hours (± 10 minutes)  
 3 hours (± 10 minutes)  3 hours (± 10 minutes)  
 -- 4 hours (± 10 minutes)  
 -- 5 hours (± 10 minutes)  
 -- 6 hours (± 10 minutes)  
 -- Administer second dose  
 -- 1 hour (± 5 minutes)  
 -- 2 hours (± 10 minutes)  
Week 2  Predosea Predosea 
 -- 0.5 hour (± 5 minutes)  
 1 hour (± 5 minutes)  1 hour (± 5 minutes)  
 -- 1.5 hours (± 5 minutes)  
 2 hours (± 10 minutes)  2 hours (± 10 minutes)  
 3 hours (± 10 minutes)  3 hours (± 10 minutes)  
 -- 4 hours (± 10 minutes)  
 -- 5 hours (± 10 minutes)  
 -- 6 hours (± 10 minutes)  
Abbreviations: PK = pharmacokinetic  
a Within 15 to 20 minutes before dosing. 
Note: For the Week [ADDRESS_125052] dose of 
study drug of the day.  
Note: For the Week [ADDRESS_125053] dose of study drug of the day. 
[IP_ADDRESS]. Blood Sample  Assessment  
Venous blood samples (6 mL) for the determination of plasma concentra tions of metopi[INVESTIGATOR_112179] (metopi[INVESTIGATOR_112130]) will be drawn by [CONTACT_112238] K2 EDTA Vacutainer® tubes at the times indicated in Table 4. Additional information 
regarding  blood collection and sample preparation are provided in the Laboratory Manual.  
Drug concentration information will be masked prior to database lock since these parameters have the potential to unblind a participant’s dose group. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  66 Sample handling and labelling   
Each aliquot of plasma will be identified as follows:  
• Line 1: Study  NG101-201  
• Line 2: randomization number,  
• Line 3: Study Day (ie, Day 1 or Week 2) and time since the first dose administered in 
clinic on that day. 
• Line 4: Plasma PK assay,  Aliquot number  
Sample S hipment and Storage  
The samples will be shipped in a container filled with enough dry ice to ensure that the samples 
are kept frozen.   
The study samples will be ship ped to the Sample Custodian as defined in the Lab Manual.   
Bioanalytical M ethod  
Plasma concentrations of metopi[INVESTIGATOR_112180]  
. using a fully validated method.  
[IP_ADDRESS]. Pharmacokinetic Parameters  
Pharmacokinetic data collected in this study may be analyzed according to a separate PK Analysis Plan and reported separately from the primary study results. 
8.8. Pharmacodynamics 
Inhibition of dopamine receptors is associated with an increase in serum prolactin levels. This is 
because dopamine has an inhibitory effect on the anterior pi[INVESTIGATOR_112181]. Thus, prolactin levels will be measured in this stud y (as indicated in  Table 5) to 
characterize the pharmacodynamic effects of NG101.  Blood samples for serum prolactin 
assessment will be sent to the central laboratory . Results of prolactin level measurements after the pre -dose assessment on Day 1 will remain blinded  until database lock . 
Note that during the following visits, study drug will be administered in the clinic:  
• Day 1:  first dose in the clinic, and second dose of the day in the clinic for those 
participants in the Intense PK subset  
• Week 1:  a dose in the clinic (ie, not necessarily the first dose of the day)  
• Week 2:  first do se of the day in the clinic 
• Week 12:  a dose in the clinic (ie, not necessarily the first dose of the day)  
 

Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  67 Table 5: Serum Prolactin Sampling Times  
Study Day  All Participants  
(± Time window)  Intensive PK Subset  
(± Time window)  
Screening Visit  Screening Visit  Screening Visit  
Day 1  Predosea Predosea 
 1 hour (± 5 minutes)  1 hour (± 5 minutes)  
 -- 2 hours (± 5 minutes)  
 -- 3 hours (± 10 minutes)  
 -- 6 hours (± 10 minutes)  
Week 2  Visit  Predosea Predosea 
 1 hour (± 5 minutes)  1 hour (± 5 minutes)  
 -- 2 hours (± 10 minutes)  
 -- 3 hours (± 10 minutes)  
 -- 6 hours (± 10 minutes)  
Week 12  or E/D Visit  Predosea Predosea 
 1 hour (± 5 minutes)  1 hour (± 5 minutes)  
EoS / Follow -up Visit  EoS / Follow-up Visit  EoS / Follow-up Visit  
Abbreviations: E/D = Early discontinuation; EoS = End of study; PK = pharmacokinetic  
a Within [ADDRESS_125054] exploratory economic analyses and will include: 
• Number and duration of medical care encounters, including surgeries, and other 
selected procedures (in patient  and outpatient) 
• Duration of hospi[INVESTIGATOR_059] (total days  or length of stay, including duration by [CONTACT_54006] 
[eg, intensive care unit ]) 
• Number and type of diagnostic and therapeutic tests and procedures 
• Outpatient medical encounters and interventions (including physician urgent care clinic 
or emergency room visits, tests and procedures, and medications). 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  69 9. Statistical Considerations  
9.1. Sample Size Determination  
A total of approximately 280 participants will be randomized to achieve an estimated 
224 participants completing the 12 -week treatment period (and approximately 56 participants per 
treatment arm). At least [ADDRESS_125055] idiopathic gastroparesis. Up to approximately 140 participants 
can be cannabinoid users, and of these, approximately 56 can be marijuana users. 
A sample size of 280 participants provides approximately 83% power to detect a mean treatment 
difference in the nausea severity score of 1.0 (on an 11-point scale) between an active dose group 
versus placebo at the [ADDRESS_125056] deviation of 1.8, 
a 20% drop-out rate, and a 2- sample t -test. 
9.2. Populations for Analyses  
The following populations are defined: 
Population Description  
Enrolled  All participants who sign the ICF . 
Intensive PK All Enrolled participants who consented to the intensive PK 
sampling. Pa rticipants  will be analyzed according to the study 
medication they actually received . 
Intent- to-Treat (ITT)  All Enrolled participants who are randomized. Participants will be analyzed according to the study medication to which they were randomized. 
Per Protocol  (PP)  All participants in the ITT population who do not have any major protocol violations. Participants will be analyzed according to the study medication they actually received. 
Safety  All participants  who take at least 1 dose of study drug . Participants 
will be analyzed according to the study drug they actually received . 
9.3. Statistical Analyses  
The statistical analysis plan (SAP) will be finalized prior to unblinding  and will include a more 
technical and detailed description of the statistical analyses described in this section. This section 
is a summary of the planned statistical analyses of the  most important endpoints , including 
primary and key secondary endpoints. 
9.3.1. General considerations 
Continuous variables will be summarized using the number of observations, mean, standard 
deviation (SD) median, minimum, and maximum. Categorical variables will be summarized 
using frequency counts and percentages. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  70 9.3.2. Efficacy  Endpoints  
The following algorithm will be applied to the daily GI assessments in the DIGS -DD and other 
GI assessments to create the baseline and weekly treatment period scores:  
• A participant’s baseline score will be the mean of the scores during the 2- week 
Pretreatment Period  (ie, each weekly score is the mean of the daily scores)  
• For each week in the 12- week T reatment P eriod, a participant’s score for that week will 
be the mean of the daily scores for that week.  
• Change from baseline for a particular week in the T reatment P eriod is that week’s score 
minus the baseline score.  
• If a participant has < 4 non -missing values for a week, the weekly score will be set to 
missing.  
[IP_ADDRESS]. Primary Efficacy Endpoint  
The primary efficacy endpoint is the change from baseline at Weeks 7 through 12 for the nausea 
severity score on the DIGS -DD (described in Section 8.3.1 ). 
The primary efficacy endpoint will be analyzed using a mixed -effect model for repeated 
measures (MMRM) on the weekly mean change from baseline scores in  the T reatment Period 
(ie, Weeks 1 through 12). The model will have treatment group, baseline nausea score, sex, 
gastroparesis etiology, cannabinoid use, study week, treatment group × study week (interaction 
effect), baseline nausea score × study week (int eraction effect), sex × study week (interaction 
effect), and gastroparesis etiology × study week (interaction effect), and cannabinoid use × study 
week (interaction effect) as fixed effects and participant as a random effect. The average value 
across Weeks 7 through 12 will be calculated for each treatment group using the MMRM along 
with the difference between each NG101 group versus the placebo group. 
The primary analysis will be performed on the PP population using an observed- case analysis for 
handling missing data. For each NG101 group versus the placebo group, the average value across 
Weeks 7 through 12 will be tested at the 2-sided 0.05 level.   
Subgroup analyses on the primary endpoint will be perform ed on the randomization stratification 
factors (sex, gastroparesis etiology, and cannabinoid use) to assess the consistency of treatment 
effect. Additional s ensitivity and supportive analyses for the primary endpoint analysis will be 
provided in the SAP. 
The primary analysis will not exclude or censor observations due to rescue medication use. 
Supplemental analyse s which exclude observations due to rescue medication use will be detailed 
in the SAP.  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  71 9.3.3. Key Secondary Efficacy E ndpoints  
The following are the set of key secondary endpoints. These endpoints are derived from the 
PROs in the DIGS -DD assessment (described in Section  8.3.1).  
• Change from baseline at Weeks 7 through 12 in the number of discrete epi[INVESTIGATOR_112182]  
• Change from baseline at Weeks 7 through 12 in the early satiety  severity score  
• Change from baseline at Weeks [ADDRESS_125057]- prandial f ullness severity score  
• Change from baseline at Weeks 7 through 12 in the abdominal pain severity score 
• Change from baseline at Weeks 7 through 12 in the total severity score (nausea, early satiety, post-prandial fullness, and abdominal pain) 
These endpoints will be analyzed in a  manner similar to the primary endpoint (Section  [IP_ADDRESS]), 
the difference being that the baseline nausea severity score covariate will be replaced wi th the 
corresponding baseline value for the endpoint being analyzed. 
9.3.4. Additional Secondary Efficacy Endpoints  
Below are the set of additional secondary endpoints . The analysis methods for the additional 
secondary endpoints will be provided in the SAP. 
• Change from baseline at Weeks 7 through 12 in the number of hours of nausea per 
24-hour period. This endpoint is derived from the Gastroparesis – Additional Daily 
Assessments described in Sectio n [IP_ADDRESS]. 
• Change from baseline at Weeks 7 through 12 in the number of hours of abdominal pain 
per 24- hour period reported. This endpoint is derived from the Gastroparesis – 
Additional Daily Assessments  described in Section  [IP_ADDRESS].  
• Change from baseline at Weeks 7 through 12 in the vomiting severity score. This endpoint is derived from the vomiting PROs in the DIGS -DD assessment (described in 
Section  8.3.1).  
• Percent of nausea- free days. The percent of nausea- free days is derived from a score of 
zero on the nausea component of DIGS- DD. 
• Change from baseline to Week 12 in PGI- S score. The PGI -S endpoint is derived from 
the PGI -S questionnaire described in Section  8.3.6. 
• Change from baseline to Week 12 in PGI-C score. The PGI -C endpoint is derived from 
the PGI -C questionnaire described in Section  8.3.7. 
• Change from baseline to Week 12 in the PAGI -SYM. The PAGI -SYM is composed of 
20 items and 6 subscales (see Section  8.3.3). Subscale scores are calculated by 
[CONTACT_112239]; scores vary from 0 (none or absent) to 5 (very severe) ( Revicki et al. 2004 ). The overall PAG I-SYM score is the average of the 
6 subscale scores ( Rentz et al. 2004 ).   
• Change from baseline to Week 12 in the PAGI -QOL  total score . The PAGI -QOL 
assessments are presented  in Section  8.3.4. Each of the 5 PAGI- QOL dimensions are 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  72 calculated by [CONTACT_112240]. 
The PAGI -QOL total score is calculated by [CONTACT_112241] ( de la Loge et al. 2004).  
• Change from baseline to Week 12 in total and subscale scores on the NP . The NP 
assessments are described in Section  8.3.5. The Total NP score is calculated as the 
percent of total points scored. Similarly, the 3 dimensions scores are calculated as the percent of total points scored of the assessments associated with that dimension.  
• Change from baseline at Week 4 in each of the 5 symptom scores on t he DIGS -DD: 
nausea, vomiting, early satiety, post- prandial fullness , and abdominal pain. These 
endpoints are derived from the DIGS -DD assessment (described in Section  8.3.1).  
• Change from baseline in gastroparesis symptoms as measured by [CONTACT_112242] (GCSI- DD). The GCSI -DD is described in 
Section  8.3.2. 
• Change from baseline to Week 12 in Treatment Satisfaction score. The Treatment 
Satisfaction endpoint is derived from the Treatment Satisfaction questionnaire described 
in Section 8.3.8. 
• Weekly use of rescue medication: As described in Section 6.5.1, rescue medication use 
will be captured in the daily diary.  
• PK parameters  
• Change from baseline in prolactin levels  at indicated timepoints . 
9.3.5. Exploratory E ndpoint(s)  
The following are exploratory endpoints: 
• Change from baseline at Weeks 7 through 12 in the feeling of  abdominal fullness 
severity score. This endpoint is derived from the Gastroparesis – Additional Daily 
Assessments described in Section  [IP_ADDRESS].  
• Change from baseline at Weeks 7 through 12 in the abdominal bloating severity score. 
This endpoint is derived from the Gastroparesis – Additional Daily Assessments 
described in Section  [IP_ADDRESS]. 
• Level of improvement reported on the Nausea Improvement assessment (see 
Section  8.3.9).  
• Association of PK parameters and changes in gastroparesis symptom PRO scores.  
• Association of PK parameters and safety assessments.  
• Achievement of threshold levels of improvement or worsening in each of the 4 numeric rating scale symptom assessment s on the DIGS -DD (nausea, vomiting, early satiety, 
post-prandial fullness, and abdominal pain).   
• Composite symptom severity scores 
• Number of visits to healthcare providers (see Section 8.12).  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  73 • Association of serum glucose levels and HgbA1c with gastroparesis symptom PRO 
scores.  
The analysis methods for the exploratory endpoints will be provided in the SAP. Additional 
exploratory endpoints may also be defined in the SAP and / or the PK Analysis Plan . 
9.3.6. Safety Endpoints  
The safety endpoints are the incidence of TEAEs, TEAESIs (eg, dopamine- receptor antagonist 
effects  and alpha -[ADDRESS_125058] effects), and TESAEs; evaluation of clinical safety laboratory 
assessments, vital signs, ECG results, and physical exam findings. 
AEs will be coded using the Medical Dictionary for Regulatory Activities. Incidence rates for 
TEAEs will be summarized overall, by [CONTACT_764], and by [CONTACT_112243]. Treatment- emergent AESIs and SAEs will also be summarized by 
[CONTACT_1570].  
Summary descriptive statistics will be provided for other safety parameters (laboratory tests, 
ECG parameters, and vital signs).  
9.4. Interim Analyses  
To assist with designing future studies , an interim analysis of this study may be performed. 
Selected sponsor members will be unblinded at the treatment group level, remaining blinded to subject- level treatment assignments. The results of this interim analysis will not be used to 
modify the study design or stop the study early due to positive efficacy results.  
9.5. Data Monitoring Committee (DMC) and Data Safety Monitoring 
Board (DSMB) 
A Data Monitoring Committee (DMC) comprised of representatives from the sponsor and CRO 
will review blinded data on an ongoing basis.  
An unblinded independent safety review conducted by a Data Safety Monitoring Board (DSMB) 
will be triggered if any of the following conditions are met: 3 or more participants in the study 
exhibit extrapyramidal symptoms (EPS); [ADDRESS_125059] neuroleptic malignant syndrome (NMS); 3 or more participants are discontinued due to orthostatic hypotension- related 
adverse events (AEs); other events considered of high clinical significance by [CONTACT_112244]. The DSMB will then make any recommendations to the sponsor regarding conduct of the study. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  74 10. Supporting Documentation and Operational Considerations  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1. Regulatory and Ethical Considerations 
This study will be conducted in accordance with the protocol and with the following: 
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines  
• Applicable ICH Goo d Clinical Practice (GCP) Guidelines  
• Applicable laws and regulations 
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents 
(eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_112245]/IEC before the study is initiated.  
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants. 
The investigator will be responsible for the following: 
• Providing written summaries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
[CONTACT_1201]/IEC  
• Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
• Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations  
10.1.2. Financial Disclosure  
Investigators and sub- investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  75 10.1.3. Informed Consent Process  
The investigator or his/her representative will explain the nature of the study to the participant or 
his/her legally authorized representative and answer all questions regarding the study. 
Participants must be informed that their participation is voluntary. Participants or their legally 
authorized representative will be required to sign a statement of informed consent that meets the 
requirements of [ADDRESS_125060] (HIPAA) requirements, where applicable, and the I RB/IEC or study center.  
The medical record must include a statement that written informed consent was obtained before 
the participant was enrolled in the study and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF. 
Participants must be re -consented to the most current version of the ICF(s) during their 
participation in the study.  
A copy of the ICF(s) must be provided to the participant or the participant’s legally authorized 
representati ve. 
A participant who is rescreened is not required to sign another ICF if the rescreening occurs within  28 days from the previous ICF signature [CONTACT_568].  
Participants willing to provid e a sample for genetic analysis will sign consent via the ICF. 
10.1.4. Data Protection 
Participants will be assigned a unique identifier by [CONTACT_456]. Any participant records or datasets that are transferred to the sponsor will contain the identifier only; participant names or any information which would make the participant identi fiable will not be transferred.  
The participant must be informed that his/her personal study -related data will be used by [CONTACT_20004]. The l evel of disclosure must also b e 
explained to the participant who will be required to give consent for their data to be used as 
described in the informed consent  
The participant must be informed that his/her medical records may be examined by [CONTACT_112246], by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668]. 
10.1.5. Committees Structure  
Data Safety Monitoring Board 
If an independent safety review committee is nee ded, a Data Safety Monitoring Board (DSMB) 
will be available on an ad hoc basis. The committee will include members who each have 
expertise in at least 1 of the following: neurology, cardiovascular disease, endocrinology, 
gastroenterology and statistics.  Additional details are available in the DSMB Charter.  
10.1.6. Dissemination of Clinical Study Data  
The sponsor is committed to making study -related data available in accordance with standard 
industry procedures. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  76 10.1.7. Data Quality Assurance 
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator is 
responsible for verifying that data entries are accurate and co rrect by [CONTACT_112247].  
The investigator must maintain accurate documentation (source data) that supports the information entered in the CRF.  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct a ccess to source data documents.  
Monitoring details describing strategy, methods, responsibilities and requirements, including handling of noncompliance issues and monitoring techniques (central, remote, or on- site 
monitoring) are provided in the  Data Monitoring Plan. 
The sponsor or designee is responsible for the data management of this study including quality checking of the data. 
The sponsor assumes accountability for actions delegated to other individuals (eg, Contract 
Research Organizations).  
Study monitor s / CRAs will perform ongoing source data verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements.  
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by [CONTACT_1732] 2 years after shipment and delivery of the drug for investigational 
use is discontinued, or as long as required by [CONTACT_427], whichever is longer . No records 
may be destroyed during the retention period without the written approval of the sponsor. No 
records may be transferred to another location or party without written notification to the 
sponsor. 
10.1.8. Source Documents  
Source documents provide evide nce for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site.  
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consist ent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or transfer records, depending on the 
study. Also, current medical records must be available.  
The d efinition of what constitutes source data can be found in the Data Management Plan.  
Neurogastrx, Inc .   NG101 -[ADDRESS_125061] been collected and a stu dy-site closure visit has been performed.  
The investigator may initiate study -site closure at any time upon discussion with the sponsor or 
designee , provided there is reasonable cause and sufficient notice is given in advance of the 
intended termination.  
Reasons for the early closure of a study site by [CONTACT_11004]: 
• Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, the sponsor's procedures, or GCP guidelines 
• Inadequate recruitment of participants by [CONTACT_093]  
• Discontinuation of further study drug development 
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_11005]. The investigator shall promptly inform the participan t and should assure 
appropriate participant  therapy and/or follow-up 
10.1.10. Publication Policy  
The results of this study may be published or presented at sc ientific meetings. If this is foreseen, 
the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments.  
The sponsor will comply with the re quirements for publication of study results. In accordance 
with standard editorial and ethical practice, the sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a 
coordinating investigator [INVESTIGATOR_12992]. 
Authorship will be determined by [CONTACT_27495]. 
  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  78 10.2. Appendix 2: Prohibited and Permitted Medications  
Prohibited Medications:  
Unless otherwise stated, the following medications are excluded within the previous 14 days or 
7 half- lives (whichever is longer) before the Screening Visit. Note that many of these 
medications have more than one reason for exclusion; in those cases, they are only listed once. 
Chronic use of systemic 
glucocorticoids  Systemic short course  (≤ 7 days) , inhaled, and topi[INVESTIGATOR_112183]  
D2 agonists  / partial 
agonists/  antagonists  Agonists:  
• Apomorphine, bromocriptine, cabergoline, pramipexole, ropi[INVESTIGATOR_11122].  
Partial Agonists:  
• Brexpi[INVESTIGATOR_4253], cariprazine.  
Antagonists:  
• Metoclopramide, domperidone.  
• 1st generation antipsychotics (typi[INVESTIGATOR_112184]): 
Phenothiazine drugs:  
Chlorpromazine, fluphenazine, levomepromazine, pericyazine, perphenazine, pi[INVESTIGATOR_112185], prochlorperazine, promazine, 
promethazine (except as rescue medication), thiethylperazine, 
thioridazine, trifluoperazine, triflupromazine.  
Non-phenothiazine drugs:  
Benperidol, clopenthixol, clotiapi[INVESTIGATOR_050], droperidol, flupenthixol, 
fluspi[INVESTIGATOR_112186], haloperidol, loxapi[INVESTIGATOR_050], pi[INVESTIGATOR_3924], thiothixene, zuclopenthixol.  
• 2nd generation antipsychotics (atypi[INVESTIGATOR_112187]- dopamine antagonists): aripi[INVESTIGATOR_4253], 
asenapi[INVESTIGATOR_050], clozapi[INVESTIGATOR_050], iloperidone, lurasidone, olanzapi[INVESTIGATOR_050], olanzapi[INVESTIGATOR_050]  / fluoxetine, paliperidone, quetiapi[INVESTIGATOR_050], risperidone, 
ziprasidone.  
Drugs associated with NMS  Carbamazepi[INVESTIGATOR_050], mibefradil  
Drugs associated with 
orthostatic hypotension • Antihypertensive agents with alpha -[ADDRESS_125062] 
activity (eg, terazosin  prazosin, doxazosin); agents with 
preferential selectivity for alpha -1a receptors in the prostate are 
allowed if blood pressure chang e upon standing at the Screening 
Visit is ≤ 10 mm Hg. ) 
• Others: bretylium, dronabinol, tizanidine.  
Acetylcholinesterase inhibitors  Donepezil, galantamine, neostigmine, pyridostigmine, rivastigmine. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  79 Drugs affecting gastric 
motility  • Drugs with known pharmacological activity at 5-
hydroxytryptophan (HT)1, 5-HT3, or 5 HT4 receptors (eg, 
ondansetron [except as rescue medication] cisapride, mosapride, prucalopride, tegaserod, tropi[INVESTIGATOR_14960], granisetron, dolasetron, naratriptan, sumatriptan, and zolmitriptan). Note: buspi[INVESTIGATOR_112188] a stable dose for at least 3 months prior to the Screening 
Period and can remain on the same stable dose for the duration of 
the study.  
• Anti-choliner gic and anti -muscarinic agents (eg, benztropi[INVESTIGATOR_112189], biperiden, clomipramine, darifenacin, dicyclomine, 
flavoxate, hyoscyamine, oxybutynin, propantheline, scopolamine, solifenacin, tolterodine, trihexyphenidyl, and trospi[INVESTIGATOR_1890]). Note: inhaled ipratropi[INVESTIGATOR_112190].  
• GLP -1 receptor agonists (eg Dulaglutide, Lixisenatide)  
• Pramlintide  
• Acarbose  
• All narcotics either alone or in combination (eg, codeine, diphenoxylate, morphine, paregoric, and propoxyphene). Notes: narcotics used as anesthesia for an esophagogastroduodenoscopy 
require a 5 -calendar -day wash -out prior to the 
participant  
entering the Pretreatment Period. Loperamide may be used as needed (prn) for diarrhea. Occasional use (up to 2 times per week) of tramadol is permitted for pain.  
• Macrolide antibiotics (eg, azithromycin, clarithromycin, erythromycin, spi[INVESTIGATOR_112191], telithromycin, troleandomycin).  
• Any fundic -relaxing agents not otherwise excluded such as, but 
not limited to, clonidine, nitrates, and triptan containing medications. Note: intermittent use (no more than once a week) of triptan -containing medications is permitted to treat migraine 
headache.  
• Other medicines which may affect gastric emptying (eg, 
colchicine and misoprostol). Note: linaclotide and lubiprostone 
may be used to treat concurrent constipation.  
Clinical P-glycoprotein inhibitors  Amiodarone, carvedilol, dronedarone, itraconazole, lapatinib, lopi[INVESTIGATOR_054], propafenone, quinidine, ranolazine, ritonavir, saquinavir, tamoxifen, telaprevir, tipranavir, verapamil.  
Any investigational or 
imported drugs that have not been approved for human use by [CONTACT_112248], Inc .   NG101 -[ADDRESS_125063] 30 days prior to the Screening Visit and should intend to 
maintain their usual medication regimen throughout the study. Insulin and other medications for 
glucose control can be adjusted as needed.  
The following concomitant medications are permitted during the study: 
Cannabinoids  Cannabinoid (eg, marijuana, CBD) use provided that use is stable over the 
previous [ADDRESS_125064] not be expected to increase during the 
study.  
D2 antagonists  / H 1 
antagonists  Promethazine (25 mg) up to 2 times / day as an anti -emetic rescue medication  
5HT [ADDRESS_125065]  Ondansetron (4 mg) up to 2 times / day as an anti -emetic rescue medication.  
A 4 mg dose of ondansetron may be repeated after 60 minutes if relief is 
insufficient. 
Alpha 1 receptor 
antagonists  Prostate specific inhibitors of alpha - receptors (eg, tamsulosin) if at Screening 
the systolic BP decreases ≤ 10 mm Hg upon standing for 1 minute . 
Glucocorticoids  Systemic short course  (≤ 7 days) , inhaled, and topi[INVESTIGATOR_112192] . 
Drugs affecting gastric motility  • Buspi[INVESTIGATOR_112193] (provided that the participant has been on a stable dose for at least 3 months prior to the Screening Period and can remain on the same stable dose for the duration of the study).  
• Inhaled ipratropi[INVESTIGATOR_112194].  
• Loperamide, as needed (prn), for diarrhea.  
• Tramadol (up to 2 times per week) for pain.  
• Triptan -containing medications (no more than once a week) for 
migraine headache.  
• Linaclotide, plenacatide, Miralax, Magnesium based laxatives, bisacodyl and senna  for concurrent const ipation.  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  82 Other Screening 
Tests  • Highly sensitive s erum and urine human chorionic gonadotropin (hCG) 
pregnancy test (as needed for women of childbearing potential)b 
• Serum testosterone test (for male participants only)  
• Serology (HIV antibody, hepatitis B surface antigen [HBsAg], and hepatitis C virus antibody)  
• Urine drug test  (eg, amphetamines, barbiturates, benzodiazepi[INVESTIGATOR_1651], cannabinoids, 
cocaine, methadone, opi[INVESTIGATOR_858], phencyclidine) . The results of each test must be 
entered into the CRF.  
NOTES:  
a If TSH is above ULN at Screening then free T4 will be checked.  
b  Local urine testing will be standard for the protocol unless serum testing is required by [CONTACT_112249]/IEC.  
All events of ALT ≥ 3 × upper limit of normal (ULN) and bilirubin ≥  2 × ULN (>  35% direct bilirubin) or ALT 
≥ 3 × ULN which may indicate severe liver injury (possible Hy’s Law), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis).  
Investigators must document their review of each laboratory safe ty report , with designation for 
clinically significant (CS ) / not clinically significant (NCS ) for out of range results. 
Laboratory  / analyte results that could unblind the study (eg, prolactin test results) will not be 
reported to investigative sites or other blinded personnel until the study has been unblinded or for 
safety issues . 
  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  90 10.6. Appendix 6: Contraceptive Guidance and Collection of Pregnancy 
Information  
Definitions:  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile (see below).  
 If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before first dose of study drug, additional evaluation should be considered. 
Women in the following categories are not considered WOCBP: 
1. Premenarchal  
2. Premenopausal female with 1 of the following:  
• Documented hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy  
For individuals with permanent infertility due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion should be applied to dete rmining study entry. 
Note: Documentation can come from the site personnel’s : review of the participant’s medical 
records, medical examination, or medical history interview.  
3. Postmenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.  
o A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with more than one FSH measurement is required.  
• Females on HRT and whose menopausal status is in doubt will be required to use one of the non-estrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  91 Contraception Guidance:  
CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
Highly Effective Methodsb That Have Low User Dependency  
• Implantable progestogen -only hormone contraception associated with inhibition of ovulationc 
• Intrauterine device  
• Intrauterine hormone -releasing system (IUS)c 
• Bilateral tubal occlusion  
• Vasectomized partner  
• (Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual 
partner of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an 
additional highly effective method of contraception should be used. Spermatogenesis cycle is approximately 
90 days.) 
Highly Effective Methodsb That Are User Dependent  
• Combined (estrogen - and progestogen -containing) hormonal contraception associated with inhibition of 
ovulationc 
o oral 
o intravaginal  
o transdermal  
o injectable  
• Progestogen -only hormone contraception associated with inhibition of ovulati onc 
o oral 
o injectable  
• Sexual abstinence  
(Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study drug . The reliability of sexual abstinence 
needs to be evaluated in relation t o the duration of the study and the preferred and usual lifestyle of the 
participant.)  
a) Contraceptive use by [CONTACT_103092].  
b) Failure rate of <1% per year when used consistently and correctly. Typi[INVESTIGATOR_107921].  
c.) If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines , acceptable 
contraceptive methods are limited to those which inhibit ovulation as the primary mode of action.  
Note: Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational a menorrhoea method (LAM) are not acceptable methods of contraception 
for this study. Male condom and female condom should not be used together (due to risk of failure with 
friction)  
 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  92 Collection of Pregnancy Information 
Male participants wi th partners who become pregnant  
• The investigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This applies only to male participants who receive NG101 . 
• After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the investigator will record pregnancy information on the appropriate form and submit it to the sponsor within 24 hours of learning of the partner’s pregnancy. The 
female p artner will also be followed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to the sponsor. Generally, the follow-up will be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure.  
Female P articipants who become pregnant  
• The investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study. The initial information will be recorded on the appropriate form and submitted to the sponsor within 24 hours  of 
learning of a participant's pregnancy.  
• The participant will be followed to determine the outcome of the pregnancy. The investigator will collect follow -up information on the participant and the neonate and the 
information will be forwarded to the sponsor. Generally, follow -up will not be required 
for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of 
pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) 
or indication for the procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be reported 
as an AE or SAE.  
• A spontaneous abortion (occurring at < 22 weeks gestational age) or still birth (occurring 
at > 22 weeks gestational age) is always considered t o be an SAE and will be reported as 
such.  
• Any post-study pregnancy related SAE considered reasonably related to the study drug  
by [CONTACT_55901]  8.5.4. While the 
investigator is not obligated to actively seek this information in former study participants, 
he or she may learn of an SAE through spontaneous reporting. 
• Any female participant who becomes pregnant while participating in the study will 
discontinue study drug or be withdrawn from the study. 
  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  93 10.7. Appendix 7: Estimated Glomerular Filtration Rate  
The Chronic Kidney Disease Epi[INVESTIGATOR_10444] [CKD- EPI] equat ion should be used 
to calculate estimated glomerular filtration rate (eGFR). The CKD -EPI [INVESTIGATOR_112195]:  
eGFR = 141 × min(S cr/κ, 1)α × max(S cr/κ, 1)-1.209 × 0.993Age × 1.018 [if 
female] × 1.159 [if black] 
Where:  
Scr = serum creatinine in mg/dL  
κ = 0.7 if female  
κ = 0.9 if male  
α = -0.329 if female 
α = -0.411 if male 
min indicates the minimum of S cr/κ or 1 
max indicates the maximum of S cr/κ or 1  
  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  94 10.8. Appendix 8: Genetics  
Use/Analysis of DNA  
• Genetic variation may impact a  participant’s response to study drug, susceptibility to, 
and severity and progression of disease. Variable response to study drug may be due to 
genetic determinants that impact drug absorption, distribution, metabolism, and 
excretion; mechanism of action of the drug; disease etiology; and/or molecular subtype 
of the disease being treated. Therefore, where local regulations and IRB/IEC allow, a blood sample will be collected for DNA analysis from consenting participants.  
• DNA samples will be used for research related to  NG101 or gastroparesis and related 
diseases. They may also be used to develop tests/assays including diagnostic tests 
related to  NG101 and gastroparesis . Genetic research may consist of the analysis of one 
or more candidate genes or the analysis of genetic markers throughout the genome (as appropriate). 
• DNA samples will be analyzed genetic variations associated with clinical responses. 
Additional analyses may be conducted if it is hypothesized that this may help further 
understand the clinical data.  
• The results of genetic analyses may be reported in the clinical study report (CSR) or in a 
separate study summary.  
• The sponsor will store the DNA samples in a secure storage space with adequate measures to protect confidential ity. 
• The samples will be retained while research on  NG101 or gastroparesis continues but 
no longer than 10 years or other period as per local requirements.  
 
  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  95 10.9. Appendix 9: Abbreviations  
Abbreviation Definition 
AE Adverse event  
AUC  Area under the plasma concentration -time curve  
AUC 0-inf Area under the plasma concentration -time curve from time 0 extrapolated to infinity  
BP Blood pressure  
CI Confidence interval  
CKD-EPI  [INVESTIGATOR_112196]/F Total clearance  
Cmax Maximum plasma concentration  
CNS  Central nervous system  
CRF Case report form  
CV Cardiovascular 
DIGS -DD Diabetic and Idiopathic Gastroparesis Symptoms Daily Diary  
DMC  Data Monitoring Committee  
DSMB  Data Safety Monitoring Board  
ECG Electrocardiogram  
E/D Early discontinuation  
eGFR  Estimated glomerular filtration rate  
EoS End of study  
EPS Extrapyramidal symptoms 
FDA  Food and Drug Administration  
GEBT  Gastric emptying breath test  
GCSI-DD Gastroparesis Cardinal Symptom Index Daily Diary  
GI Gastrointestinal  
hERG human Ether -à-go-go-related gene 
IB Investigator’s Brochure  
ICH International Conference on Harmonisation  
ICF Informed consent form  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
IRT Interactive response technologies 
ITT Intent -to-treat  
Neurogastrx, Inc .   NG101 -[ADDRESS_125066] model for repeated measures  
NMS  Neuroleptic malignant syndrome  
NP Nausea Profile 
OH Orthostatic hyp otension  
PAGI -QOL  Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life  
PAGI -SYM  Patient Assessment of Upper Gastrointestinal Disorders-Symptoms  
PD Pharmacodynamic 
PK Pharmacokinetic  
PGI-C Patient Global Impression of Change  
PGI-S Patient Global Impression of Severity  
PO Orally  
PRO Patient reported outcomes  
QID 4 times daily  
Q6H Every 6 hours  
QOL  Quality of life  
QTcF  QT interval corrected using Fridericia’s formula 
SAD  Single ascending dose  
SAE  Serious adverse event  
SAP Statistical Analysis Plan  
SoA Schedule of Activities  
Study drug  NG101  
t1/[ADDRESS_125067]  Upper limit of normal  
US [LOCATION_002]  
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  97 11. References  
Achari R, Hosmane B, Linnen P, et al. Effects of Oral and Intravenous Terazosin and Head‐up 
Tilt on Blood Pressure Responses in Patients with Hypertension. The Journal of Clinical Pharmacology. 1998;38(6):545-53. 
Arbus L and Pare nte C. Use of metopi[INVESTIGATOR_112197]. 
Therapeutique (La Semaine des hopi[INVESTIGATOR_112198]). 1971;47(5):469-71. 
Arnaud B and Sportouch M. Value of metopi[INVESTIGATOR_112122] (Vogalene) in the prevention and treatment 
of postoperative vomiting in ocular surgery.(Apropos of 100 cases). Archives d'ophtalmologie et 
revue generale d'ophtalmologie. 1972;32(1):63. 
Badji F, Chaussade S, Grandjouan S, et al. Comparative study of the effects of metoclopramide 
and metopi[INVESTIGATOR_112199]: a manometric 
study in healthy subjects. In Annales de gastroenterologie et d'hepatologie 1988;24(7):369-374. 
Ballester HA, Toyosato TA, Chulia M, et al. Clinical study of metopi[INVESTIGATOR_112200]. 
Revista espanola de las enfermedades del aparato digestivo. 1980;58(1):41. 
Barale F, Berthet F and Magnin P. Comparative study of the intestinal spasmolytic properties of 
metoclopramide and metopi[INVESTIGATOR_112122]. Anesthesie, analgesie, reanimation. 1977;34(1):47-54. 
Berry GH, Duncan W and Bowman CM. The prevention of radiation sickness. Report of a 
double blind random clinical trial using prochlorperazine and metopi[INVESTIGATOR_112122]. Clinical Radiology. 1971;22(4):534-7. 
Bertrand J and Thillier JL. Action of metopi[INVESTIGATOR_112201]. Double -blind study using 
external digestive electromyography. La Nouvelle presse medicale. 1975;4(32):2319. 
Bethune-Volters A, Chidiac J, Bensaoula O, et al. A randomized, double- blind trial assessing the 
efficacy and safety of sublingual metopi[INVESTIGATOR_112202]-induced delayed emesis. Anti-cancer drugs. 2006;17(2):217-24. 
Camilleri M, Parkman HP, Shafi MA, et al. Clinical Guideline: Management of Gastroparesis. 
The American Journal of Gastroenterology. 2013;108(1):18. 
Chey W, Shiff S, Schneier H et al. Two Years on Linaclotide: Tolerability and Treatment 
Satisfaction in IBS -C Patients With and Without Diarrhea: Presidential Poster. American Journal 
of Gastroenterology. 2014;109. Choung RS, Locke III GR, Schleck CD, Zinsme ister AR, et al. Risk of Gastroparesis in Subjects 
with Type 1 and 2 Diabetes in the General Population. The American Journal of 
Gastroenterology. 2012;107(1):82. 
Croom KF and Keating GM. Metopi[INVESTIGATOR_112122]. American Journal of Cancer. 2006;5(2):123-36. da Silva RM. Syncope: epi[INVESTIGATOR_623], etiology, and prognosis. Frontiers in Physiology. 
2014;5:471. 
de la Loge C, Trudeau E, Marquis P, et al. Cross-cultural development and validation of a patient 
self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: The 
PAGI -QOL©. Quality of Life Research. 2004;13(10):1751- 62. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  98 Food and Drug Administration (FDA). Gastroparesis: Clinical Evaluation of Drugs for 
Treatment – Guidance for Industry. Food and Drug Administration Center for Drug Evaluation 
and Research. Silver Spring, MD. 2019. 
Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic 
hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 
2011;21(2):69-72. 
Gastric Emptying Breath Test (GEBT). Summary of Safety and Effectiveness Data (SSED). 
https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110015b.pdf . Accessed O ctober 2019. 
Gosselin A, Gosselin M, and Bretagne JF. Manometric effects of metopi[INVESTIGATOR_112203] (author's transl). La semaine des hopi[INVESTIGATOR_112198]: organe fonde par l'Association 
d'enseignement medical des hopi[INVESTIGATOR_112204]. 1981;57(5- 6):291 -5. 
Guerin MT, Guerin RA, and Salaün O. Therapeutic value of metopi[INVESTIGATOR_112205]. La Presse Medicale. 1969;77(24):893-. 
Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic 
malignant syndrome diagnostic criteria using the Delphi method. Journal of Clinical Psychiatry. 2011;72(9):1222. 
Herrstedt J, Jorgensen M, Angelo HR. The effect of food on serum concentrations of 
metopi[INVESTIGATOR_112122]. British Journal of Clinical Pharmacology. 1990;30(2):237-43. 
Herrs tedt J, Sigsgaard T, Handberg J, et al. Randomized, double-blind comparison of 
ondansetron versus ondansetron plus metopi[INVESTIGATOR_112148]-
based chemotherapy in patients with cancer. Journal of clinical oncology. 1997a;15(4):1690-6. 
Herrstedt J, Sigsgaard T, Handberg J, et al. Randomized, double-blind comparison of 
ondansetron versus ondansetron plus metopi[INVESTIGATOR_112148]-
based chemotherapy in patients with cancer. Journal of clinical oncology. 1997b;15(4):1690-6. 
Israel L and Rodary C. Treatment of nausea and vomiting related to anti- cancerous multiple 
combination chemotherapy: results of two controlled studies. Journal of International Medical 
Research. 1978;6(3):235-40. 
Jaffe JK, Paladugu S, Gaughan JP, et al. Characteristics of nausea and its effects on quality of 
life in diabetic and idiopathic gastroparesis. Journal of Clinical Gastroenterology. 
2011;45(4):317-21.  
Lebeau B, Depi[INVESTIGATOR_11958] A, Giovannini M, et al. French Ondansetron Study Group. T he efficacy of a 
combination of ondansetron, methyiprednisolone and metopi[INVESTIGATOR_112206] a dual antiemetic treatment in cisplatin -based chemotherapy. Annals of 
oncology. 1997;8(9):887-92. 
Muth ER, Stern RM, Thayer JF, et al . Assessment of the multiple dimensions of nausea: the 
Nausea Profile (NP). Journal of Psychosomatic Research. 1996;40(5):511-20. 
NIH- NINDS (National Institutes of Health —National Institute of Neurological Disorders and 
Stroke). Postural Tachycardia Syndrome Information Page - Postural orthostatic tachycardia 
syndrome (POTS).  https://www.ninds.nih.gov/Disorders/All- Disorders/Postural- Tachycardia-
Syndrome- Information -Page#disorders-r1. Accessed July 26, 2019. 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  99 Paradis B and Brault R. A new antiemetic: vogale n (metopi[INVESTIGATOR_112207] 9965 RP). Laval medical. 
1967;38(10):901-7. 
Parkman HP. Gastroparesis, Postprandial Distress. In: Gastrointestinal Motility Disorders 2018 
(pp. 269-281). Springer, Cham. 
Parkman HP, Camilleri M, and Revicki D. The American Neurogastroenterology and Motility 
Society (ANMS) Gastroparesis Cardinal Symptom Index Daily Diary (GCSI- DD) User Manual. 
September 2018.  
Pi[INVESTIGATOR_112208]. Extrapyramidal symptoms with atypi[INVESTIGATOR_16709]. Drug safety. 2005;28(3):191-
208. 
Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the 
patient assessment of upper gastrointestinal symptom severity index (PAGI- SYM) in patients 
with upper gastrointestinal disorders. Quality of Life Research. 2004;13(10):1737 -49. 
Revicki D A, Rentz AM, Tack J, et al. Responsiveness and interpretation of a symptom severity 
index specific to upper gastrointestinal disorders. Clinical Gastroenterology and Hepatology. 
2004;2(9):769-77. 
Revicki DA, Lavoie S, Speck RM, et al. The content validity of the ANMS GCSI-DD in patients 
with idiopathic or diabetic gastroparesis. Journal of Patient-reported Outcomes. 2018;2(1):61. 
Rodary C, Elman A, Durand M, et al. Double blind randomized trial of metopi[INVESTIGATOR_112122]: for 
postoperative nausea and vomiting after cholecystectomy. InAnnales de l'anesthesiologie 
francaise. 1979;20(2): 118-120. 
Sigsgaard T, Herrstedt J, Handberg J, et al. Ondansetron plus metopi[INVESTIGATOR_112209]. Journal of Clinical Oncology. 2001;19(7):2091-7. 
Stein B, Everhart KK, Lacy BE. Gastroparesis. Journal of Clinical Gastroenterology. 
2015;49(7):550-8. 
Vogalene (15 mg capsule). Summary of Product Characteristics (2017). Teva Sante. Wadhwa V, Mehta D, Jobanputra Y, et al. Healthcare utilization and costs associated with 
gastroparesis. World journal of gastroenterology. 2017;23(24):4428. 
Whitledge JD, Ali N, Basit H, et al. Presyncope. [Updated 2019 Jun 4]. In: StatPearls [Internet]. 
Treasure Island (FL): StatPearls Publishing; 2019 Jan -. Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK459383/ 
Neurogastrx, Inc .   NG101 -201 
 
CONFIDENTIAL  100 INVESTIGATOR’S STATEMENT  
 
 
I agree to conduct the trial in accordance with the protocol and with all applicable government  
regulations and good clinical practice guidance.  
 
 
 
 
 
              
Investigator’s Signature       [CONTACT_112253]’s Name  